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Abstract 
The existence of unfair differences or disparities in access to and quality of health care is well 
known. However, the nature of disparities at different stages of the health seeking pathway and 
interventions to reduce them are less clear. Applying the tools of statistics and quasi 
experimental design-- interrupted time series, propensity score matching, hierarchical models—
we can analyze how care is accessed in low, middle and high income countries and assess for 
disparities. The results are sometimes surprising and underscore the need to generate context 
specific evidence to ensure targeting of programs. 
 
My first paper evaluates the impact of a controversial policy, mandating of health insurance, on 
reducing disparities in health care access and affordability. Using longitudinal survey data from 
five states in USA (2002-2009), I show that living in MA, where health insurance is mandated, 
results in a higher probability of being insured and having a personal doctor and lower 
probability in forgoing care due to costs as compared to similar border states. The beneficial 
effect of the mandate is greatest in traditionally ―disadvantaged‖ groups defined by race, income, 
education or employment status. 
 
My second paper examines gender disparities in access to medicines in sub Saharan Africa--
Uganda, Kenya, Nigeria, Ghana, Gambia. Using medicines specific survey data, I construct a iv 
 
novel seven stage access to medicines pathway and assess gender disparities along it applying 
the Institute of Medicine framework. Contrary to prevailing belief, I find few gender differences 
in unadjusted outcomes which cease to be significant on controlling for health status and country 
characteristics. 
 
My third paper assesses disparities by educational attainment in process and outcomes of care. I 
use unique data extracted from an electronic medical record of diabetic patients in Mexico City. 
Using a matching algorithm, I control for only differences in health need and find few significant 
differences in processes and outcomes of care. The unmatched traditional regression based risk 
adjustments tend to overestimate the significance and magnitude of the association. 
 
The three papers demonstrate the need to use more sophisticated statistical tools to appropriately 
measure disparities and ensure the effectiveness of health programs. 
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Chapter 1: 
 
Effects of health care reforms on coverage, access, and disparities: 
Quasi-experimental analysis of evidence from Massachusetts
a 
   
                                                       
a This chapter has been published as Pande AH, Ross-Degnan D, Zaslavsky AM, Salomon JA. Effects of healthcare 
reforms on coverage, access, and disparities: quasi-experimental analysis of evidence from Massachusetts. Am J 
Prev Med. 2011; 41(1):1–8. 2 
 
 
Abstract  
Background 
The 2010 Patient Protection and Affordable Care Act (PPACA) has been controversial. The 
potential impact of national health care reform may be considered using a similar set of state-
level reforms including exchanges and a mandate, enacted in 2006 in Massachusetts. 
Purpose 
To evaluate the effects of reforms on health care access, affordability and disparities. 
Design 
Interrupted time series with comparison series. 
Setting/Participants 
Longitudinal survey data from 2002 to 2009 from the Behavioral Risk Factor Surveillance 
System including 178,040 non-elderly adults residing in Massachusetts, Vermont, New 
Hampshire, Rhode Island and Connecticut. Analysis was conducted from January-August 2010. 
Intervention 
Massachusetts 2006 health care reform, which included an individual health insurance mandate. 
Main Outcome Measure 
Being uninsured, having no personal doctor, and forgoing care due to cost, evaluated in 
Massachusetts and four comparison states before (2002-2005) and after (2007-2009) the health 3 
 
care reform. Effects on disparities defined by race, education, income and employment were also 
assessed. 
Results 
 Living in Massachusetts in 2009 was associated with a 7.6 percentage point (3.9, 11.3) higher 
probability of being insured, 4.8 percentage point (-0.9,10.6) lower probability of forgoing care 
due to cost, and a 6.6 percentage point (1.9, 11.3) higher probability of having a personal doctor, 
compared to expected levels in the absence of reform, defined by trends in control states and 
adjusting for socio-economic factors. The effects of the reform on insurance coverage attenuated 
from 2008 to 2009.  In a socio-economically disadvantaged group, the reforms had a greater 
effect in improving outcomes on the absolute but not relative scale. 
Conclusions 
Health care reforms in Massachusetts, which included a health insurance mandate, were 
associated with significant increases in insurance coverage and access. The absolute effects of 
the reform were greater for disadvantaged populations. This is important evidence to consider as 
debate over national health reform continues. 
 
 4 
 
Introduction 
The 2010 Patient Protection and Affordable Care Act (PPACA) expands insurance coverage and 
mandates health insurance for most Americans.
1,2 These reforms have been particularly 
controversial. Opponents have symbolically repealed the bill in the US House of 
Representatives. Virginia and Florida courts have exempted residents from the individual 
mandate and the ongoing legal case against the mandate is likely to be decided eventually by the 
US Supreme Court.
3  
 
The experience of Massachusetts (MA) provides evidence on the impact of similar state health 
care reforms. In April 2006, MA legislature enacted comprehensive health reform requiring all 
state residents to carry a minimum level of health insurance, subject to penalties for non-
compliance starting in 2008.
4 To make coverage more affordable the reform expanded Medicaid, 
subsidized private insurance, and set up the Commonwealth Connector to help individuals find 
suitable insurance. While an estimated 406,000 people have gained insurance in MA between 
June 2006 and March 31, 2009,
5 attributing causal effects to the reforms has been  challenging.  
 
Studies examining the effects of MA reforms in specific health care facilities are limited, have 
mixed results, and are difficult to generalize.
6,7 Surveys within MA before and after the reform 
have indicated higher insurance coverage, access, and use of health care in the post-reform 
period.
8,9,10,11,12,13 However, the pre-post design of these studies does not control for underlying 
secular trends and the lack of comparison to areas outside of Massachusetts might fail to account 5 
 
for regional trends. One prior study
13 using difference-in-difference methods to compare 
insurance coverage in Massachusetts and three control states (New Jersey, New York and 
Pennsylvania) found a significant drop in uninsurance among non-elderly adults in 
Massachusetts, but its design did not adjust for secular trends or consider outcomes other than 
insurance.  
 
To our knowledge, only one other study has looked at the effect of MA reform on a similar range 
of outcomes.
14 However, this study did not examine data before the reform, so could not account 
for pre-existing trends. Previous literature suggests that MA had unique factors leading up to the 
reforms such as a lower rate of uninsurance; broader Medicaid participation;
 and a generous, 
taxpayer-funded pool of money for
 uncompensated care.
15 The prior study‘s small sample sizes 
limited its ability to discern effects within specific racial and economic subgroups. The study 
also only tracked the impact of the reform until 2008 and thus failed to observe results after the 
beginning of the economic downturn.
11  
 
This study uses longitudinal survey data over an eight-year period and a strong quasi-
experimental design to examine a range of policy-relevant outcomes, both overall and in the 
disadvantaged groups that were its main target. The objective is to provide rigorous empirical 
evidence on the potential immediate and medium-term impacts of the MA reforms, including its 
individual insurance mandate, on health care outcomes. 
 6 
 
Methods 
Study Design 
The 2006 MA health care reforms were exploited as a naturally occurring quasi-experiment and 
trends in key outcomes were evaluated from 2002-2009, using an interrupted time series with 
comparison series design, the strongest observational design for making causal inference.
16 
Analysis was conducted from January-August 2010. All study participants in MA were 
considered to be exposed to the reforms, including the health insurance mandate (i.e. an 
―intention to treat‖ design), and those living in Rhode Island, Vermont, New Hampshire and 
Connecticut constituted the comparison group. These four states border MA and have similar 
socio-economic environments.  
 
The comparability of the sample was assessed. Next, the unadjusted differences in the study 
outcomes (overall and for specific subgroups) were examined before and after the reform.  
Finally, an individual-level interrupted time series analyses was run to control for potential 
differences between the samples over time. A similar subgroup analysis of the effects of the 
reform on disparities was conducted. 
 
Data Source 
Publicly available data from the Behavioral Risk Factor Surveillance System (BRFSS), an 
annual cross-sectional telephone survey of the civilian, non-institutionalized population that is 7 
 
designed and funded by the Centers for Disease Control and Prevention and conducted by states 
was used.
17 Households are contacted through random digit dialing.  Since the effects of the 
reform are expected to be greatest for non-elderly adults not yet eligible for Medicare, the 
analysis was limited to respondents ages 18 to 64. 
 
Outcome Measures 
The primary outcomes were responses to three questions: (1) ―Do you have any kind of health 
care coverage, including health insurance, prepaid plans such as HMOs, or government plans 
such as Medicare?‖ (2) ―Do you have one person you think of as your personal doctor or health 
care provider?‖ (Respondents who answered ―no‖ were asked to clarify whether there was more 
than one person or no person.)  (3) ―Was there a time in the past 12 months when you needed to 
see a doctor but could not because of cost?‖  For the third question, the analysis was restricted to 
2003-2009 due to inconsistent wording in 2002.  
 
Several individual-level covariates were included to adjust predictions: age, sex, marital status, 
education, employment, household size, and household income. Race was categorized as non-
Hispanic white, non-Hispanic black, Hispanic, and other/mixed race.  Annual household income 
was categorized as <$25,000; $25,000 - $49,999; and $50,000. 
20 Education was classified as 
having completed high school or not. Employment categories distinguished wage employment, 
self-employment, and all other categories (being unemployed, retired, homemaker, student, or 8 
 
unable to work). Marital status was classified as being married compared to never married, 
divorced, widowed, separated, or a member of an unmarried couple. 
 
Statistical Analyses  
An interrupted time series analysis of individual data was used to estimate changes in the three 
outcomes before and after 2006.  Using logistic regression models, the primary independent 
variables of interest were terms capturing changes in outcomes in 2007, 2008, and 2009 in 
Massachusetts, compared to those in control states. To aid interpretation, coefficients from the 
models were used to predict the adjusted effects on the percentage scale. The effects were 
expressed as the probability of each outcome for a standard population living in MA minus the 
counterfactual probability of the outcome had the population not been exposed to the 2006 
reform. The analyses was run on 100 bootstrapped samples and the mean and standard error of 
the bootstrapped estimates were used to determine confidence intervals. 
 
The effect of the reform on disparities was examined. A ―disadvantaged‖ group was defined that 
had characteristics associated with uninsurance at baseline. The disadvantaged group included 
people who were black, Hispanic, of other/mixed race, self-employed, with less than high school 
education, or an annual household income below $50,000. Similar interrupted time series models 
were used to examine how changes differed in the two groups on both the relative and absolute 
scales.  The significance of relative effects was evaluated with two-sided tests of the coefficients 
that captured the effects of the reform in MA in 2007, 2008, and 2009.
19 Absolute effects were 9 
 
determined by predicting the effects in the disadvantaged compared to advantaged groups using 
the coefficients from the interrupted time series models. 
 
Sensitivity Analyses 
Three sensitivity analyses were run. First, the model was run in the survey sub-sample that was 
65 years or older. This population already had high levels of insurance through Medicare so 
should have been minimally affected by the reform; differences in outcomes observed may 
signify other uncontrolled factors such as the economic downturn. Second, the models were re-
estimated excluding one control state at a time to evaluate the robustness of the results to the 
choice of controls. Third, the model specification was tested by running two alternative models, 
one in which the effects of the reform were assumed to change linearly (on the logistic scale) 
after 2006 and another in which equal trends in MA and control states before 2006 were 
assumed.  
 
All tests were 2-sided with p<0.05 considered statistically significant. BRFSS sampling weights 
and post-stratification adjustments were used to account for differences in probabilities of 
selection and non-response, and to partially correct for non-coverage of non-telephone 
households.
17 All analyses were performed using Stata, version 10.1 (Stata Corp, College 
Station, Texas). 
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Results 
The study population (n= 178,040) represented nearly 5 million US adults ages 18 to 64 living in 
MA and the four control states over the seven analysis years. At baseline the groups had similar 
composition in terms of household size, sex, education, wage employment, and income (Table 
1).  The average age in both groups was 40 years, and both samples comprised 51 percent 
females, with overwhelming majorities having at least a high school education.  MA had a 
different racial mix before and after the reforms which likely reflects year-to-year sampling 
differences. Race was controlled for in the final model to account for these differences. 
Overall Effects 
Unadjusted estimates show a significant decrease in uninsurance rates and in forgoing care due 
to cost in MA compared to control states, with the greatest decrease in 2008 (Figure 1). 
Uninsurance in MA decreased from 11.0 percent in 2002 (95 per cent CI: 10.0, 12.1) to 5.1 
percent (4.5, 5.8) in 2008, increasing slightly to 6.5 percent (5.5, 7.4) in 2009. Uninsurance rates 
in the control states were relatively flat from 13.3 percent (12.4, 14.1) in 2002 to 12.3 (11.4, 
13.3) in 2009. Although there was a decrease in the MA respondents not having a personal 
doctor in 2007, differences were substantially reduced in the next two years.  
 
Adjusting for individual covariates in the time-series regression models, the interaction terms 
between MA and the post-reform years were found to be significant, suggesting that MA 
residents were significantly more likely to be insured and have a personal doctor, and 
significantly less likely to forgo care due to cost, compared to expected levels in the absence of 
reform, defined by trends in the comparison states (Table 2). Living in Massachusetts in 2009  11 
 
Table 1: Characteristics of the study population before and after the 2006 reforms 
   2002-2005  2007-2009  Both Periods Combined 
Characteristic  MA 
Control 
States  MA 
Control 
States  MA 
Control 
States 
n  24,829  61,935  40,353  50, 923  65, 182  112, 858 
Mean (SD)                   
Age  39.9 (.1)  40.5 (.1)  41.0 (.1)  41.4 (.1)  40.4 (.1)  40.9 (.1) 
Household Size  3.2 (.0)  3.2 (.0)  3.3 (.0)  3.2 (.0)  3.3 (.0)  3.2 (.0) 
Frequency (SD)                   
Male  49.0 (.4)  49.3 (.3)  49.1 (.4)  49.5 (.4)  49.0 (.3)  49.4 (.2) 
Education (>High 
School)  92.6 (.2)  93.1 (.2)  93.6 (.2)  94.8 (.2)  93.0 (.2)  93.9 (.1) 
Married  56.5 (.4)  60.1 (.3)  60.9 (.4)  62.30 (.4)  58.4 (.3)  61.1 (.2) 
Employment                  
  Self-Employed  9.2 (.2)  10.2 (.2)  8.8 (.2)  10.0 (.2)  9.0 (.2)  10.3 (.1) 
  Wage Employed  64.5 (.4)  61.9 (.4)  66.3 (.4)  64.4 (.4)  65.2 (.3)  65.1 (.2) 
Race                  
  White  81.6 (.3)  84.9 (.3)  78.4 (.4)  85.5 (.3)  80.2 (.3)  85.2 (.2) 
  Black  3.9 (.2)  3.7 (.1)  5.2 (.2)  3.2 (.1)  4.4 (.1)  3.5 (.1) 
  Hispanic  9.2 (.3)  7.2 (.2)  9.3 (.3)  6.6 (.2)  9.3 (.2)  6.9 (.1) 
  Other/ Mixed  5.3 (.2)  4.2 (.1)  7.2 (.2)  4.7 (.2)  6.1 (.2)  4.4 (.1) 
Annual Household 
Income                  
  < $25,000  17.4 (.3)  16.2 (.2)  16.0 (.3)  13.5 (.3)  16.8 (.2)  15.0 (.2) 
  $25,000-$49,999  24.0 (.4)  25.8 (.3)  18.7 (.3)  19.5 (.3)  21.7 (.3)  23.0 (.2) 
  > $50,000  58.6 (.4)  58.0 (.3)  65.3 (.4)  67.0 (.4)  61.5 (.3)  62.0 (.2) 
Bold indicates a significant difference at p <.05 
   12 
 
Figure 1: Unadjusted annual estimates of study outcomes over time in Massachusetts and 
control states. Columns show results in (1) the overall sample; (2) the disadvantaged subsample; 
(3) the advantage subsample. Rows show outcomes for (1) percent uninsured; (2) percent unable 
to see a doctor due to cost and (3) percent not having a personal physician. 
Disadvantaged group is defined as black, Hispanic, other race, low income, with less than high 
school education, or self-employed; advantaged group is defined as white, high income, with at 
least a high school education, or not self-employed. 
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Table 2: Adjusted impacts of the Massachusetts health insurance mandate showing the 
reforms to have a significant effect on study outcomes 
 Variables
*  No health insurance 
Medical cost as 
barrier  No personal doctor 
   n = 159,795  n= 141,701  n = 159,811 
   Odds Ratio (95 % CI)  Odds Ratio (95 % CI)  Odds Ratio (95 % CI) 
Massachusetts  0.93  (0.76 ,1.13)  0.82  (0.63 ,1.06)  1.06  (0.89 ,1.27) 
Year  0.99  (0.95 ,1.03)  1.07  (1.00 ,1.15)  0.95  (0.92 ,0.99) 
Change in Level  1.04  (0.86 ,1.25)  0.93  (0.76 ,1.15)  1.28  (1.08 ,1.52) 
Change in Trend  1.03  (0.95 ,1.12)  0.99  (0.90 ,1.09)  1.00  (0.92 ,1.08) 
Massachusetts x Year  1.05  (0.98 ,1.13)  1.05  (0.93 ,1.18)  1.08  (1.01 ,1.15) 
Massachusetts x 2007
†  0.55  (0.41 ,0.75)  0.80  (0.54 ,1.19)  0.67  (0.51 ,0.87) 
Massachusetts x 2008
†  0.29  (0.20 ,0.42)  0.55  (0.33 ,0.90)  0.59  (0.43 ,0.82) 
Massachusetts x 2009
†  0.35  (0.22 ,0.55)  0.54  (0.29 ,1.00)  0.56  (0.38 ,0.83) 
Black  1.34  (1.16 ,1.55)  1.27  (1.11 ,1.44)  1.14  (1.00 ,1.3) 
Hispanic  1.99  (1.81 ,2.19)  1.37  (1.23 ,1.53)  1.99  (1.81 ,2.17) 
Other  1.23  (1.07 ,1.41)  1.48  (1.27 ,1.72)  1.54  (1.37 ,1.73) 
Low Income (<$25,000)  6.07  (5.49 ,6.72)  5.45  (4.92 ,6.04)  2.52  (2.32 ,2.74) 
Middle Income ($25,000-$49,999)  3.81  (3.50 ,4.16)  3.42  (3.13 ,3.73)  1.79  (1.67 ,1.91) 
Household Size  1.04  (1.01 ,1.06)  1.05  (1.03 ,1.08)  0.96  (0.94 ,0.98) 
High School Education or more  0.58  (0.52 ,0.65)  0.84  (0.75 ,0.94)  0.74  (0.67 ,0.82) 
Employed for Wages  0.81  (0.75 ,0.87)  0.77  (0.72 ,0.83)  1.07  (1.00 ,1.15) 
Self-Employed  2.58  (2.35 ,2.84)  1.52  (1.37 ,1.68)  1.67  (1.52 ,1.84) 
Married  0.57  (0.53 ,0.61)  0.74  (0.68 ,0.80)  0.76  (0.71 ,0.81) 
Age  0.98  (0.98 ,0.99)  0.99  (0.99 ,0.99)  0.96  (0.96 ,0.96) 
Male  1.77  (1.66 ,1.88)  0.90  (0.84 ,0.96)  2.24  (2.13 ,2.37) 
†Main predictors of interest, estimating the effect of the MA reform in 2007, 2008 and 2009, in relation to the 
expected levels under no reform defined by trends in comparison states. *Massachusetts is a dummy variable 
capturing if the individual lived in MA or not; year is an integer variable ranging from –4 for data from 2002 to 3 for 
data from 2009; change in level is a dummy variable coded 0 if the data were from before 2006 and 1 if after; and 
change in trend is a variable coded 0 if the data were from before 2006, 1 if 2007, 2 if 2008 and 3 if 2009.  
Bold is results significant at the .05 level. 14 
 
was associated with a 65 percent (95% confidence interval: 45, 78) reduction in the odds of 
being uninsured, a 46 percent (0.2, 71) reduction in the odds of forgoing care due to cost, and a 
44 percent (17, 62) reduction in the odds of not having a personal doctor, adjusting for race, 
income, household size, education, employment, age, sex and marital status. The magnitude of 
the protective effect on uninsurance rates attenuated from 2008 to 2009. 
  
On adjusting for known confounders, by 2009 the reforms were associated with a 7.6 percentage 
point (3.9, 11.3) higher probability of being insured, 4.8 percentage point (-0.9,10.6) lower 
probability of forgoing care due to cost, and a 6.6 percentage point (1.9, 11.3) higher probability 
of having a personal doctor for an average person in the population. 
Socially Disadvantaged Subgroup Analyses 
Unadjusted estimates show that the disadvantaged group (n=96,327) experienced substantially 
poorer outcomes overall than the advantaged group (n=84,871) prior to the reforms (Figure 1). 
After the reforms, there were significant decreases in uninsurance rates and forgoing care due to 
cost for both groups. 
 
The adjusted time series models for the disadvantaged group revealed that in 2009 the reforms 
resulted in a 63 percent (40, 77) reduction in the odds of being uninsured in MA compared to the 
comparison states, a 49 percent (0.1, 74) reduction in the odds of forgoing care due to cost, and a 
51 percent (22, 70) reduction in the odds of not having a personal doctor. For the advantaged 15 
 
group, living in MA resulted in a significant reduction only in uninsurance rates compared to 
comparison states. 
 
In absolute terms, improvements in the disadvantaged group were greater for all three outcomes 
in all three-post reform years (Figure 2). However, the relative change in effect size between the 
disadvantaged and advantaged groups were non-significant in adjusted time series models for all 
three outcomes in all three post-reform years (results not shown). 
 
Sensitivity Analyses 
To consider the possibility of bias resulting from other changes unique to MA during the reform 
period, a parallel analysis among the Medicare-eligible population in MA and the control states 
(n=48,224) was conducted. No significant differences were found in the probabilities of forgoing 
care due to cost or not having a personal physician, suggesting that the main findings in non-
elderly adults were not contaminated by other factors. The Medicare-eligible population in MA 
did have a significantly lower rate of uninsurance than the corresponding population in the 
control states after the reforms. This is to be expected as before the reforms the uninsured elderly 
population in MA was mostly low income (71 per cent earned less than $25,000 annually) or 
Hispanic (18 per cent) -- both groups targeted by the reforms.  
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Figure 2 
Estimated effect of Massachusetts reform on study outcomes in disadvantaged and advantaged 
groups showing a greater absolute effect of the reform in disadvantaged groups. All estimates 
control for household size, employment, age, sex, and marital status. Estimates for the 
disadvantaged group also control for race, income and education as they vary within this sub-
population. 
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Examining the robustness of the results, neither direction nor magnitude of effects changed 
substantially when any one comparison state was excluded. Alternate model specifications 
resulted in effects within the confidence intervals of the effect sizes in the original model, 
indicating that the original specification was robust. As expected, the model that assumed post-
reform trends to be linear estimated smaller changes in outcomes in 2008 and larger changes in 
2009. The model that assumed similar pre-reform trends in MA and comparison states estimated 
somewhat smaller effects of the reform and was more sensitive to outliers. 
 
Discussion  
Our analyses revealed three important findings. MA health reforms had large and statistically 
significant overall effects in reducing rates of uninsurance, reducing the likelihood of forgoing 
care due to cost, and improving access to a personal physician. However, the positive effects of 
the reform attenuated from 2008 to 2009. This is consistent with other analyses, which have 
attributed this result to the global economic crisis.
11 It may also indicate reduced impact of the 
reform over time. Future studies should monitor longer-term effects, especially on final health 
outcomes that cannot be assessed in such a short period. Finally, the reforms had a greater 
absolute effect among disadvantaged groups, although the relative differences compared to 
advantaged groups were not significant. This may be due to the disadvantaged group having 
substantially worse outcomes at baseline and greater scope for improvement. 
 18 
 
Our observation of increased access to personal physicians in MA after the reforms is especially 
relevant. Anecdotal evidence suggested that it might be more difficult to find a personal 
physician due to the numbers of newly insured MA residents.
20 Surveys of physician wait times 
in MA have pointed to long waits but changes since the reform were unclear.
22 However, neither 
of these studies used pre-reform data as a comparison.  
 
Our study has substantial application to the ongoing national debates over health reform. The 
federal health reform and the MA reform are similar in use of health insurance mandates, health 
insurance exchanges, and expansion of coverage. This may suggest significant national gains in 
coverage and access due to the implementation of the PPACA.
22 A recent analysis of the MA 
reforms suggested that mandating health care was responsible for an increase in enrollment of 
healthy individuals as compared to when healthcare was subsized.
13  
 
However, the implementation of the national reform could differ substantively. The MA reforms 
were passed with virtually universal support; there were only two dissenting votes in both houses 
of the legislature.
22 This allowed public officials to embark on a widespread social marketing 
campaign which could have been responsible for the acceptance and success of the mandate. The 
experience with national reform has been markedly different, with implementation of the 
mandate producing polarizing debate and inspiring organized resistance. The penalties for non-
compliance with the insurance mandate in the national reform ($695 per person to a maximum of 
$2085 per family) are also three to four times higher than in MA ($218 for an individual and 19 
 
$437 for a family in 2007), which could imply different quantitative effects of the reforms at the 
national level.  
 
The study contrasts with prior studies in several ways.  A stronger quasi-experimental design and 
more recent data to estimate the effect of the MA reform were used.
8,10,11, 13,14, 23 The design 
accounts for pre-existing trends in MA and control states since the sensitivity analysis and the 
literature suggests that MA may have had unique factors leading up to the reforms
15. The 
assumptions were validated by testing if the reforms had an effect in the group with Medicare 
eligibility; we found few significant differences between MA and control states in this over-65 
population, which supports the inference about the effects of the reform. Similar to other work, 
we demonstrate that the MA reforms had a significant effect overall in improving coverage and 
health access. However, unlike other studies, we demonstrate that the reform had a significant 
absolute effect among disadvantaged groups. Because racial and economic disadvantage often 
overlap, the subgroup analysis pooled traditionally disadvantaged racial and socioeconomic 
groups.  
 
A number of limitations should be noted. The interrupted time series model has seven data 
points. Short time series are useful for causal inference as extra baseline data addresses threats to 
internal validity; extra post-intervention observations indicate persistence of the impact; and use 
of comparison groups strengthens inference. 
16 While one of the control states, Vermont, 
introduced a limited set of health reforms concurrently,
24 the sensitivity analysis excluding 
Vermont showed no significant difference in results.  20 
 
 
The use of BRFSS data could also limit external validity. Median response rates in all years of 
analysis ranged from 72 to 77 percent. The CASRO response rates were lower, ranging from 35 
to 63 percent cent across states.
25  Changes in non-response over time could bias results; 
however, non-reponse biases in random-digit dialing (RDD) telephone surveys are probably 
modest,
26,27 and the use of sampling weights partially corrects for non-response bias. Since data 
were obtained by self-report, recall and other potential biases may also be relevant.  The rise of 
cell phones and increase in call screening may be responsible for falling response rates in RDD 
surveys.
28,29 However, compared to mail-based surveys, RDD surveys have been found to be 
representative, cost-effective, and useful for contacting non-English speaking households (who 
are more likely to be uninsured).
30 
 
In summary, the results from Massachusetts provide strong evidence on the effectiveness of a 
package of health care reforms, including an individual mandate, in increasing access to health 
care, especially for disadvantaged groups. This is important to consider as implementation of the 
federal health reform and potential repeal of the mandate are debated. 
   21 
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Abstract 
Objective 
Equitable access to medicines is critical for effective health care. Gender disparities in medicines 
access are widely assumed, but few empirical studies have tested this hypothesis. 
Methods 
We analyzed data from the WHO and Medicines Transparency Alliance (MeTA) Household 
Medicines Surveys, completed in Gambia, Ghana, Kenya, Nigeria and Uganda in 2007-2008 
(n=5,161). We formulated a novel seven-stage access to medicines pathway along which we 
systematically assessed gender disparities. In addition, we used multinomial logistic regression 
models to operationalize the Institute of Medicine (IOM) definition of disparity in a step wise 
manner and examined gender relationships with source of care, source of prescriptions, and 
source of obtaining medicines. 
Findings 
We observed significant gender differences in fewer than 10 per cent of unadjusted outcomes, 
with boys (under age 5) more likely to receive prescriptions from doctors or nurses and girls 
from more informal sources of care.  No other significant gender differences were seen in health 
seeking behavior, sources of care, numbers or cost of medicines, or adherence, for either adults 
or children. Controlling for health status and country characteristics, there were no significant 
gender disparities in source of care, prescriptions, and medicines. 
Conclusion 27 
 
 We found little evidence of gender disparities in access to medicines in five Sub-Saharan 
African countries. Our findings are consistent with emerging research across other developing 
countries and underline the need for generating country and subject specific evidence to 
appropriately target interventions toward equity in health care.  
   28 
 
 
Introduction 
Access to medicines is crucial for effective health care and an important component of the 
realization of health as a human right.
1,2,3 Give equal need, if gender is the basis for differential 
access to medicines, 
4,5 this would  prevent the realization of WHO‘s goal of ―health for all‖.  
While disparities in access to medicines  due to gender in low- and middle-income countries 
have been hypothesized,
6,7 empirical evidence is lacking. Novel data from the only medicines-
focused household survey to date, implemented  by WHO and the Medicines Transparency 
Alliance (MeTA),
8 now make it possible to examine gender differences at different steps in the 
access to medicines pathway. 
 
Poor access to medicines in the public sector, and high out-of-pocket spending for medicines in 
the private sector contribute significantly to impoverishment of the poor and near-poor. 
9,
 
10 
However, studies on gender disparities in access to medicines are few and inconclusive.
 In high-
income countries (North America, Europe, Australia), research suggests greater use and spending 
on prescription medicines and greater prevalence of self-medication among women than men. 
11,12 While these differences could be due to biological factors such as unique reproductive roles 
and longer life expectancies of  women, they could also be explained by gender differences in 
perceptions of ill health, inclination to consult a medical doctor, and prescribing patterns.
6 
 
In low and middle income countries (LMIC), the link between gender and access to medicines is 
unclear. It is hypothesized that prevailing gender norms -- women‘s lack of resources, lack of 29 
 
participation in household decision making processes, values and norms that exclude or restrict 
women‘s participation in society, and legal constraints that favor men 
13 -- may disadvantage 
women and result in them using fewer medicines. 
6,14 Qualitative studies of access to 
tuberculosis treatment in Vietnam show that women delay care-seeking due to social stigma.
15 
However, female patients with HIV infection in LMICs were at least as likely as men to start 
anti-retroviral therapy, possibly due to HIV counseling and testing in reproductive care 
settings.
16, 17  
 
Using newly available WHO data, we employed a structured empirical approach, asking three 
questions. First, are there gender disparities in different stages of the access to medicines 
pathway in African countries? Second, are gender disparities evident among people with chronic 
or acute illness? Third, does the relationship between gender and medicines access differ 
between poor and less poor individuals?
 
 
We formulated a novel access to medicines pathway, drawing on the Health Access Livelihood 
Framework 
18 and the BASICS Pathway to Survival 
19 to define seven steps where gender 
differences might occur, namely: symptoms are recognized, treatment is sought, care is 
accessible, medicines are available, medicines are affordable, medicines are acceptable, and 
medicines are taken as needed (Figure 3). We applied the Institute of Medicine (IOM) definition 
of disparities in which gender differences due to the health care system or its legal and regulatory 
environments are considered disparities or unjust differences, while differences due to health 
care needs or preferences are not. 
20 In the IOM construct clinical needs are appropriate, while  30 
 
Figure 3: Access to medicines pathway: Incident illness to medicines access 
 
Steps Towards Medicines Access          Categories of Outcome Measures* 
 
 
 
*Unless specified, outcome measures refer to acute and chronic conditions.   
 
•Acute conditions reported 
•Chronic conditions reported  1. Symptoms are recognized 
 
•Treatment sought (acute only) 
2. Care is sought 
 
•Advised to take medicines/took medicines 
•Sources where care was sought (acute only)  3. Care is accessible  
 
•Number of medicines taken 
•Source of prescriptions (acute only) 
•Source of medicines (acute only) 
4. Medicines are available 
 
•Cost of medicines (full course for acute illness 
and monthly cost for chronic illness) 
•Coverage of medicines by health insurance 
5. Medicines are affordable 
 
•Opinions on access to medicines 
•Opinions on affordablity of medicines 
•Opinions on quality of medicines 
6. Medicines are acceptable 
 
•Non-adherence 
•Reasons for non-adherence 
7. Medicines regimens are 
adhered to 31 
 
differences in care due to patients‘ socioeconomic status (and correlates of socio-economic status 
such as education or household location) are unjustifiable and so are targets for 
improvements.
21,22 Inappropriately controlling for socioeconomic status or its correlates would 
cause underestimation of the magnitude of the gender effect on health. 
 
Methods 
 
Data Source  
We analyzed cross-sectional data from the Medicines Transparency Alliance (MeTA) and WHO 
Household Medicines Survey conducted in Gambia, Ghana, Kenya, Nigeria, and Uganda.
8 
Between 900 and 1080 households per country, selected based on stratified cluster sampling, 
completed the surveys between August 2007 and December 2008.
23,24  
 
The survey captured information on access to medicines for acute and chronic illnesses and 
opinions on medicines. In each household, one respondent was selected who was the main health 
care decision maker; designated caregiver for sick household members; or most knowledgeable 
about the health, health expenditures, or health care utilization of the household. The respondent 
reported on current chronic and recent acute illnesses for all household members and gave his or 
her opinions on access to, affordability, and quality of medicines. The survey collected socio-
demographic data on age, gender, and education of household members, and on household 
income.  32 
 
 
Two versions of the survey were administered. A long questionnaire, administered in Ghana, 
Kenya and Uganda, captured demographic information for each household member, and details 
on treatment for each household member who had an acute illness in the last two weeks or a 
current chronic disease. A short questionnaire, administered in Nigeria and Gambia, captured 
information on the youngest household member with an acute illness in the last two weeks and 
the oldest household member with a chronic illness. Since country specific sample sizes were too 
small for robust inferences, we pooled data from all five countries. 
 
Outcome Measures 
For each household member for whom the respondent reported a recent acute or current chronic 
illness, we constructed measures of symptom recognition and health seeking behavior. The 
resulting seventy-three indicators (binary or continuous) were classified according to a seven 
stage access to medicines pathway (Figure3 and Table 5):  
1. Symptom recognition: Presence of sets of acute symptoms (cough, runny nose, sore throat, 
ear ache; fever, headache, hot body; diarrhea, vomiting, nausea, could not eat; pain and aches; 
other;  yes/no) and chronic conditions (hypertension, high blood pressure; heart disease, heart 
attack, stroke, high cholesterol; diabetes, high blood sugar; asthma, wheezing, chronic difficulty 
breathing; HIV infection, AIDS; arthritis, chronic body pain; ulcer, chronic stomach pain; 
depression; other; yes/no).  33 
 
2. Care seeking:  Individuals reporting an acute illness sought treatment outside their homes 
(yes/no). 
3. Accessibility of care and medicines: Location where individuals sought care during their 
acute illness episode (public hospitals; public health center or dispensary; private hospital, clinic, 
physician, private pharmacy or drug seller; non-governmental organization (NGO) or mission 
hospital; other; more than one source of care; yes/no); and whether they took medicines for acute 
illness or had medicines recommended for chronic illnesses (yes/no). 
4. Availability of medicines: Type of provider who prescribed medicines during the acute 
illness episode (doctor or nurse; pharmacist or drug seller; other; more than one provider; 
yes/no); and places where medicines were obtained (public hospital; public health center; private 
pharmacy or drug seller; private health provider, NGO or mission hospital; other; more than one 
source; yes/no). Total number of medicines taken for the recent acute illness and recommended 
for chronic illnesses. 
5. Affordability of medicines: Total cost of medicines for treating the acute illness episode and 
for chronic conditions taken in the past month (in local currency). Partial or full coverage of any 
medicine for chronic illness by health insurance (yes/no).   
6. Acceptability of medicines: Respondent‘s agreement with statements on accessibility, 
affordability and quality of medicines (yes/no). 
7. Adherence to medicine regimen: Individuals having taken all medicines prescribed or 
recommended (yes/no) and agreement with reasons for not taking medicines (yes/no).  
 34 
 
Predictor Measures  
The primary predictor was the gender of the person reported to have had an acute or chronic 
condition.  In multivariate models, based on the IOM framework of disparities we included 
health status and geographic variables.
23, 24, 28 Variables adjusting for socioeconomic status (SES) 
were explored in bivariate associations, but not included in multivariable modeling. 
 
Health status variables were age (distribution based on survey design; five years and older versus 
under five years old for acute illness; 30 years and older versus under 30 years old for chronic 
conditions and 25 years and older versus under 25 years old for acceptability of medicines 
indicators) and self-reported severity of acute illness (very or somewhat serious, compared to not 
serious).  
 
Geographic variables included binary measures for whether or not the household was less than 
one hour from: a public source of care (public hospital or public health center), a private source 
of care (private or NGO hospital), or a private pharmacy or drug seller.  
 
SES variables were education, defined as whether or not the respondent (in Gambia and Nigeria) 
or patient (in Ghana, Kenya, Uganda) completed at least primary school or not, and household 
income, dichotomized as belonging to the first or second income quintile (poor) versus the 
remaining quintiles (relatively non-poor). Quintiles were calculated based on self-reported 35 
 
classification of monthly household expenditures, taking into consideration country and 
household size.  
 
Statistical Analysis 
The unit of analysis was the sick individual. Since health-seeking behavior may differ for acute 
and chronic conditions, we modeled acute and chronic conditions separately. Decisions to seek 
care could also differ for children versus adults, and some outcomes only applied to adults 
(chronic illness, opinions about treatment); we therefore modeled outcomes for children 
separately. We tested bivariate associations of the seventy-three outcomes in the access to 
medicines pathway with gender. We stratified each analysis into two age groups resulting in 146 
tests of difference of means based on a t-distribution, conservatively conducted with unequal 
variances.
26 
 
Among patients with acute illnesses, we assessed previously hypothesized gender 
differences
6,7,13,27  in source of care, source of prescriptions, and source of medicines using 
hierarchical models with clustering at the household level. Covariates were selected based on the 
IOM definition of disparities, controlling for ―justifiable differences‖ due to health status and 
geography.
21-25, 28 We used multinomial logistic regression models to estimate the adjusted risk 
ratio of seeking care or medicines at a given source. We also tested interactions of gender with 
age, income, and education as these variables could have potential moderating effects on the 
relationship between gender and access to medicines.  36 
 
 
All analyses were performed using Stata 10.0 (StataCorp, Texas) and results were considered 
significant if p0.05. 
 
Results  
 
Sample Description 
The sample consisted of 19,116 individuals in 5,161 households across five countries. 2,880 
individuals had a recent acute illness and 1,254 reported chronic illnesses (Table 3). 
 
More than half (55 per cent) of household members with recent acute illnesses or chronic illness 
were female. Men and women lived at similar distances from sources of care. Among patients 
with acute illness, men were significantly younger (mean age 13 versus 16 years) and poorer 
than women (proportion in the first two quintiles 62 per cent versus 58 per cent; Table 4).  
Among patients reporting chronic illness, men were significantly more likely to have completed 
primary school education (69 per cent versus 52 per cent).  
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Table 3: Country samples 
 
   Gambia*  Ghana  Kenya  Nigeria*   Uganda  Total 
Households (N)  900  1065  1065  1080  1051  5161 
Individuals (n)  900  5360  5853  1080  5923  19,116 
Individuals reporting 
recent acute illness  553  317  674  610  726  2880 
Individuals reporting 
recent chronic illness  176  166  300  290  322  1254 
* In Gambia and Nigeria, the short form of the survey was used which only collected limited 
demographic data from the respondent for each household. Data on acute illness was collected 
only for the youngest household member with acute illness and chronic illness for the oldest 
household member with chronic illness. In Ghana, Kenya, and Uganda, the long form of the 
survey was used which collected information on all household members with acute and chronic 
illnesses. 
 
 
Unadjusted differences 
There were few unadjusted differences by gender. Across 146 outcomes representing the seven 
stages of access to medicines pathway for two age categories, we found significant gender 
differences in less than 10 per cent (12 outcomes; Table 5). Standard errors for approximately 80 
per cent of the 146 outcomes were less than 5 per cent with many less than 1 per cent. 
 
1. Symptom recognition  
Girls and women over five years were significantly more likely than boys and men to report pain 
and aches and women under thirty were more likely to report heart conditions. Men over thirty  38 
 
Table 4: Patient characteristics  Acute Illness  Chronic Illness 
   Male  Female  Male  Female 
 Health Status  (n= 1295)  (n=1585)  (n= 556)  (n=698) 
Age (mean; years)  13.1*  16.3*  46.5  44.8 
Severity of acute illness (%)         
          Very serious  10.0  11.8  n/a  n/a 
           Somewhat serious  22.2  28.1  n/a  n/a 
           Not serious  12.8  14.7  n/a  n/a 
Country (%)         
Gambia  18.8  19.6  11.9*  15.8* 
Ghana   8.8*  12.8*  9.9*  15.9* 
Kenya  22.4  24.2  24.5*  23.5* 
Nigeria   24.4*  18.5*  29.5*  18.1* 
Uganda  25.6  24.9  24.3  26.8 
Geography (%)         
Distance from private source of care less than 1 
hour  35.3  32.8  39.6  36.3 
Distance from public source of care less than 1 
hour  40.5  39.3  42.9  41.3 
Distance from pharmacy or drug seller less than 1 
hour  47.4  49.1  51.0  51.9 
Socio economic status (%)         
Completed primary school
+   54.6  53.1  58.9*  51.6* 
Poor (monthly income in quintile 1 or 2)  61.5*  57.9*  53.0  57.9 
* differ at p<.05 
 
+ For long surveys (Ghana, Kenya, Uganda), education level is that of the patient. For short surveys 
(Gambia, Nigeria), education level is that of the household head.  39 
 
were significantly more likely to report diabetes or high blood sugar, while men under thirty 
were more likely to report other chronic conditions. Both genders reported all other acute 
symptoms and chronic conditions with similar frequency.   
 
2. Care seeking 
There were no significant gender differences in care seeking outside the home by age group for 
acute illness. All groups sought care approximately 90 per cent of the time. 
 
3. Care seeking behavior and medicines 
There were no significant gender differences by age group in medicines taken for acute 
symptoms or recommended for chronic conditions, or in source of care for acute illnesses. In 
analyses across all age groups, we found men more likely than women to seek care for acute 
illnesses at public hospitals (22.6 per cent men as compared to 19.1 per cent women; results not 
shown). 
 
4. Availability of medicines 
Boys under age five were more likely to receive prescriptions for acute conditions from a doctor 
or nurse while girls of the same age were more likely to receive prescriptions from other sources 
of care (self, household member, friend, neighbor, or traditional healer). Men and women of the 40 
 
same age took similar numbers of medicines for acute symptoms and obtained medicines with 
equal frequency from the same sources. 
 
5. Affordability of medicines 
Women under 30 years of age in Kenya spent more money on chronic medicines. There were no 
significant gender differences in total payment for acute care medicines or in reported monthly 
costs of chronic illness medicines by country. There was also no significant gender difference in 
insurance coverage for chronic illness; however, men under 30 years of age reported insurance 
coverage for any chronic care medicine half as often as women. 
 
6. Acceptability of medicines 
There were some significant gender differences in opinions about medicines. Women reported 
higher likelihood of finding needed medicines in the private pharmacy near their house and of 
obtaining prescribed medicines if insurance reimbursed part of the cost. Men were more likely to 
report that in the past their household had to borrow money or sell household possessions to pay 
for medicines and that they believed imported medicines were of better quality than locally 
manufactured ones. There were no significant gender differences in opinions about the 
affordability, quality, and accessibility of medicines. 
 
7. Adherence to medicine regimens 41 
 
There were no gender differences in reported adherence or reasons for non-adherence for acute 
or chronic medicines by age group. Reported adherence rates ranged from 84 to 87 per cent. 
 
Adjusted models of disparities  
There were no significant gender differences in source of care, prescriptions, and medicines 
when IOM concordant covariates (health status, country; results available on request) were 
included in the model (Figure 4; Web Appendix 6a-c). However, severity of illness, age, and 
country were significant predictors in some models. 
 
Are poor women differentially affected? Modification by Age, Income or Education 
In regression models, patient age, household income, and respondent completion of primary 
school education were significantly associated with source of acute care, of prescriptions, and of 
medicines, but these variables did not moderate the association between gender and source of 
acute care, prescriptions, and medicines (interaction terms not statistically significant; results 
available on request). 
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Table 5: Outcomes along the access to medicines pathway by gender and age 
Outcomes   Male  Female  Male  Female 
1)  Symptom recognition  Under 5 years  5 years and over 
a)  Acute conditions    (n=622)  (n=568)  (n=667)  (n=1012) 
i)  Cough, runny nose, sore throat, ear ache  39.4%  43.5%  32.8%  33.4% 
ii)  Fever, headache, hot body   74.3%  72.7%  66.1%  65.1% 
iii)  Diarrhea, vomiting, nausea, could not eat   26.8%  30.6%  21.3%  20.3% 
iv)  Pain, aches   15.0%  17.1%  28.6%*  34.9%* 
v)  Other
c  30.9%  26.1%  32.8%  31.5% 
  Under 30 years  30 years and over 
b)  Chronic conditions   (n=124)  (n=162)  (n=429)  (n=534) 
i)  Hypertension, high blood pressure    4.0%  8.0%  42.2%  47.4% 
ii)  Heart disease, heart attack, stroke, high cholesterol   0%*  4.3%*  7.7%  6.9% 
iii)  Diabetes, high blood sugar   3.2%  3.7%  18.2%*  11.8%* 
iv)  Asthma, wheezing, chronic difficulty breathing   28.2%  25.3%  11.0%  11.0% 
v)  HIV infection, AIDS   7.3%  8.6%  7.2%  8.1% 
vi)  Arthritis, chronic body pain   6.5%  5.6%  17.2%  21.2% 
vii) Ulcer, chronic stomach pain   12.9%  20.4%  16.8%  20.8% 
viii) Depression   2.4  2.5  2.6  3.2 
               ix)  Other
d   46.4%*  34.6%*  12.1%  10.8% 
2)  Care seeking  Under 5 years  5 years and over 
  (n=622)  (n=568)  (n=667)  (n=1012) 
                                                       
c Other acute conditions included difficulty breathing, fast breathing; convulsions, fits; could not sleep; thirst, 
sweating; or bleeding, burn, accident. 
d Other chronic conditions include cancer, epilepsy, seizures, fits, tuberculosis,  liver disease 43 
 
Outcomes   Male  Female  Male  Female 
a)  Care sought outside the home  91.2%  91.2%  90.5%  90.1% 
3)  Accessibility of c and medicines  Under 30 years  30 years and over 
 
a)  Medicine recommended for chronic disease   
(n=124) 
89.5% 
(n=162) 
89.5% 
(n=429) 
92.0% 
(n=534) 
92.2% 
  Under 5 years  5 years and over 
b)  Medicine taken during acute illness  94.4%  95.6%  94.8%  94.8 
c)  Sources of care for acute illness  (n=489)  (n=448)  (n=534)  (n=803) 
i)  Public hospital   24.1%  19.9%  21.2%  18.6% 
ii)  Public health center or dispensary   37.6%  40.0%  32.2%  34.0% 
iii)  Private hospital, clinic or physician   12.1%  12.5%  14.2%  14.9% 
iv)  Private pharmacy or drug seller   17.4%  20.3%  21.9%  20.9% 
v)  NGO, mission hospital   7.4%  6.0%  7.9%  9.3% 
vi)  Other (traditional healer, friend, neighbor)   1.4%  1.3%  2.6%  2.2% 
vii) More than one source of care   13.9%  13.0%  11.6%  11.6% 
4)  Availability of medicines   Under 5 years  5 years and over 
a)  Number of medicines for acute illness (mean)   2.7  2.7  2.4  2.5 
b)  Source of prescriptions for acute illness   (n=563)  (n=515)  (n=592)  (n=907) 
i)  Doctor, nurse  56.1%*  48.9%*  59.0%  61.5% 
ii)  Pharmacist or drug seller  11.4%  11.3%  14.2%  12.3% 
iii)  Other (self, household member, friend, neighbor,  
traditional healer) 
32.5%*  39.8%*  26.9%  26.1% 
iv)  More than one source of prescribing   3.4%  3.6%  3.6%  3.7% 
c)  Source of medicines for acute illness  (n=484)  (n=447)  (n=504)  (n=765) 
i)  Public hospital  19.3%  15.6%  15.8%  14.8% 
ii)  Public health center  35.3%  38.8%  29.5%  31.9% 
iii)  Private pharmacy, drug seller  32.1%  34.9%  42.0%  40.4% 
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Outcomes   Male  Female  Male  Female 
iv)  Private health provider  10.3%  9.4%  13.2%  13.2% 
v)  NGO, mission hospital  8.8%  6.6%  8.1%  8.7% 
vi)  Other (home,  friend, neighbor,  traditional healer)  4.5%  4.1%  4.6%  4.1% 
vii) More than one source of medicines   7.6%  8.3%  7.5%  7.0% 
  Under 30 years  30 years and over 
d)  Number of medicines for chronic illness (mean)  1.7  1.7  2.0  2.0 
5)  Affordability of medicines              
a)  Cost of all medicines for acute illness  (local currency)  Under 5 years  5 years and over 
i)  Gambia (n=189)  27.0  26.1  25.2  49.6 
ii)  Ghana (n=205)  3.1  13.2  5.5  39.9 
iii)  Kenya (n=534)  160.1  167.7  450.0  340.8 
iv)  Nigeria (n=598)  1103.3  1437.4  1408.2  1170.4 
v)  Uganda (n=423)  5219.0  3576.3  6766.1  4870.0 
b)  Cost of all medicines for chronic illness (local 
currency) 
Under 30 years  30 years and over 
i)  Gambia (n=86)  14.2  7.0  94.6  10.2 
ii)  Ghana (n=131)  4.6  8.3  238.7  7.5 
iii)  Kenya (n=156)  38.8*  261.0*  444.0  277.8 
iv)  Nigeria (n=187)  823.7  591.7  1751.8  2276.1 
v)  Uganda (n=132)  2551.8  8558.6  14092.1  4092.7 
c)  Cost covered by health insurance for at least one 
chronic illness medicine 
5.0%  11.4%  10.7%  11.8% 
6)  Acceptability of medicines (% agreeing)  Under 25 years  25 years and over 
a)  Opinions on access  (n=108)  (n=278)  (n=2402)  (n=2102) 
i)  The public health facility closest to my household 
is easy to reach  
75.9%  72.3%  68.3%  69.7% 
ii)  My household would use public health facilities 
more if the opening hours were convenient  
     
79.6% 
75.8%  76.6%  74.3% 
iii)  The public health facility closest to my house 
usually has the medicines we need  
42.6%  40.6%  37.9%  39.0% 
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Outcomes   Male  Female  Male  Female 
iv)  The private pharmacy closest to my household has 
the medicines my household needs  
60.2%  65.3%  59.7%*  63.3%* 
b)  Opinions on affordability  Under 25 years  25 years and over 
i)  My household can get free medicines at the public 
health care facility  
59.2%  63.5%  49.6%  50.5% 
ii)  Medicines are more expensive at the private 
pharmacies than at public health care facilities  
75.0%  74.5%  75.2%  75.1% 
iii)  My household can usually get credit from the 
private pharmacy if we need to  
15.7%  21.2%  22.0%  19.7% 
iv)  My household can usually afford to buy the 
medicines we need  
52.8%  49.8%  46.8%  47.6% 
v)  My household would obtain prescribed medicines 
if insurance reimbursed part of the cost  
41.7%  40.8%  36.2%*  43.0* 
vi)  In the past, my household had to borrow money or 
sell things for medicines  
50.0%  46.4%  49.4%*  44.9%* 
c)  Opinions on quality  Under 25 years  25 years and over 
i)  The quality of services delivered at public health 
facilities in my neighborhood is good  
62.6%  61.4%  63.5%  62.5% 
ii)  The quality of services delivered by private health 
care providers in my neighborhood is good  
71.0%  73.1%  65.7%  67.9% 
iii)  Imported medicines are of better quality than 
locally manufactured ones  
38.8%  34.6%  36.7*  33.4* 
7)  Adherence to medicine regimens (% respondents 
agreeing) 
Under 5 years  5 years and over 
a)  Sick person took all medicines recommended or 
prescribed for acute illness 
86.7%  84.4%  84.5%  83.5% 
b)   Reasons for not taking medicines  (n=111)  (n=99)  (n=149)  (n=244) 
i)  Symptoms have gotten better   45.0%  57.6%  38.3%  35.7% 
ii)  Someone in the household decided that medicines 
were not needed/ advised not to take/ chose a 
different treatment  
16.2%  12.1%  9.4%  10.2% 
iii)  Sick person had bad reactions to medicines in the 
past  
0.9%  3.0%  4.0%  3.3% 
iv)  The place where medicines can be obtained was 
too far away/ medicines were not available at 
public health facility/ not available at pharmacy/ 
no one had time to obtain medicines  
18.0%  17.2%  8.1%  9.8% 
v)  Our household could not afford medicines   11.7%  14.1%  7.4%  9.0% 
  Under 30 years  30 years and over 
c)  Sick person took all medicines recommended or 
prescribed for chronic illness 
88.5%  84.9%  87.8%  85.5% 
d)  Reasons for not taking medicines  (n=12)  (n=22)  (n=49)  (n=72) 
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Outcomes   Male  Female  Male  Female 
i)  Symptoms have gotten better   50.0%  50.0%  49.0%  41.7% 
ii)  Someone in the household decided that medicines 
were not needed/ advised not to take/ chose a 
different treatment  
25.0%  31.8%  20.4%  18.1% 
iii)  Sick person had bad reactions to medicines in the 
past  
16.7%  0.0%  8.2%  15.3% 
iv)  The place where medicines can be obtained was 
too far away/ medicines were not available at 
public health facility/ not available at pharmacy/ 
no one had time to obtain medicines  
25.0%  31.8%  38.8%  38.9% 
v)  Our household could not afford medicines   16.7%  18.2%  34.7%  29.2% 
 
   
Table 5 (continued) 47 
 
 
Figure 4: Predicted gender differences in medicines access outcomes for acute illness 
 (shows trends, though no difference is statistically significant) 
Fig 4a: 
Fig 4b: 
Fig 4c: 48 
 
Discussion  
 
Our research has several unique contributions. We offer one of the few methodologically 
rigorous cross-country evaluations of the widely-held belief that gender disparities 
disadvantaging women extend to all aspects of health care, including medicines access. The 
unexpected result adds much-needed evidence to the discourse about gender inequities in 
medicines access in LMIC. In addition, we are among the first to operationalize the Institute of 
Medicines definition of disparities in the study of access to medicines. 
28,29,15 
 
We did not find hypothesized inequities in medicines access disadvantaging women in LMICs.
6  
Emerging evidence from 2002 WHO World Health Survey data in 53 countries and IMS 
prescribing data in 15 mostly LMICs also suggest that women generally have similar access to 
medicines as men, when controlling for health care need.
30,31 We also found no significant 
differences in medicines access for boys and girls, consistent with results from a recent study in 
rural Bangladesh which reported no differences in prevalence of illness or care-seeking pattern 
for children 
32 and a UNICEF report 
33 showing that treatment for childhood pneumonia, 
diarrhea, and malaria did not vary by gender.   
 
Two synergistic mechanisms may explain these findings. Concepts of ―masculinity‖ may make it 
unacceptable for men to seek care and medicines.
34,35 In addition, women may have enhanced 49 
 
access to acute and chronic care medicines through reproductive and child health services in 
primary health settings.
36,37  
 
Our study has some limitations. Respondents reported outcomes on behalf of ill household 
members. If they remembered events differently for men and women, recall bias could have 
affected our results. By confining reports of acute illness to the previous two weeks, the survey 
attempted to minimize recall bias. The validity of the self-reported measure of household 
expenditures is unknown. Differential misclassification of expenditures by patient gender, 
however unlikely, might have impacted our multivariate results.   
 
Sample size for some of the subgroup analyses (e.g. cost of medicines in each country, reasons 
for non-adherence) was limited and our analyses may have lacked power to detect gender 
differences for certain outcomes. However, nearly 80 per cent of our outcomes had standard 
errors less than 5 percent. Given the large number of outcomes, we performed multiple statistical 
tests.  Adjusting for multiple testing could only have decreased the number of statistically 
significant findings, adding confidence to our overall finding of few gender-related differences. 
 
Our study was based on data from a dedicated medicines survey in five Anglophone countries in 
Sub-Saharan Africa. The sampling methodology makes results representative for the population 
that lives within fifteen kilometers of a hospital or primary health care facility, but not 
necessarily for more remote populations. Since gender norms are thought to vary by region and 50 
 
culture, we cannot necessarily generalize findings beyond the study countries. To account for 
country differences, we included country-specific fixed effects in our models.  
 
Although we did not find gender inequities in the outcomes measured, they may exist in these or 
other populations. For example, women may receive different types of medicines, or may receive 
medicines later in the course of illness, requiring studies of gender equity in quality of care.  
Also, while men and women paid approximately the same amount for medicines, women may 
have experienced the economic burden of or negotiating for medicines payment differently.  
Although the study countries varied widely on the 2010 Global Gender Gap Index with Uganda 
rated more (33 of 134 countries) and Nigeria less (118) equitable,
38 gender dynamics in Africa 
are likely different from those in Asia where studies have shown differences in access to 
medicines.
39,40, 41  
 
Our findings have recommendations directly applicable to other LMICs. To ensure efficient and 
effective use of resources, policy makers, and leaders of gender mainstreaming programs should 
use evidence to parse out exactly where disparities may occur and focus resources on these 
bottlenecks. The seven-stage access to medicines pathway proposed in our study may serve to 
identify, target, and evaluate potential gender and socioeconomic disparities in medicines.  
Disparities in one aspect of health seeking may not necessarily apply to others. 
   51 
 
 
Acknowledgements 
We thank Alan Zaslavsky and Joshua Salomon for their detailed editorial comments and 
methodological suggestions. We also thank Tom McGuire and Ben LeCook for their help 
operationalizing the IOM definition of disparities and the participants in the Harvard Health 
Policy PhD and Harvard Pharmaceutical Policy Research seminars for their suggestions on 
earlier drafts of this paper. 
 
Aakanksha Pande conducted this research as part of her Harvard Medical School (HMS) 
Fellowship in Pharmaceutical Policy Research. 
 
Funding Sources: The U.K. Department for International Development, the Harvard Merit 
Fellowship, and the HMS Fellowship in Pharmaceutical Policy Research funded this work. 
   52 
 
References 
1. Hogerzeil HV, Samson M, Casanovas JV, Rahmani-Ocora L. Is access to essential medicines 
as part of the fulfilment of the right to health enforceable through the courts? Lancet. 
2006;368(9532):305–311. 
2. Hogerzeil HV. Essential medicines and human rights: what can they learn from each other? 
Bull. World Health Organ. 2006;84(5):371–375. 
3. Committee on Economic, Social and Cultural Rights. The right to the highest attainable 
standard of health. 2000. 
4. Wagstaff A, Van Doorslaer E. Equity in health care finance and delivery. Handbook of health 
economics. 2000;1:1803–1862. 
5. Maurer J. Assessing horizontal equity in medication treatment among elderly Mexicans: which 
socioeconomic determinants matter most? Health Econ. 2008;17(10):1153–1169. 
6. Baghdadi G. Gender and medicines: an international public health perspective. J Womens 
Health (Larchmt). 2005;14(1):82–86. 
7. Bisilliat J. Introducing the Gender Perspective in National Essential Drug Programmes. 2001. 
Available at: http://apps.who.int/medicinedocs/en/d/Jh2997e/. Accessed April 25, 2011. 
8. World Health Organization. Development of Country Profiles and monitoring the 
pharmaceutical situation in countries. 2010. Available at: 
http://www.who.int/medicines/areas/coordination/coordination_assessment/en/index.html. 
Accessed October 27, 2010. 
9. Niëns LM, Cameron A, Van de Poel E, et al. Quantifying the Impoverishing Effects of 
Purchasing Medicines: A Cross-Country Comparison of the Affordability of Medicines in the 
Developing World. PLoS Med. 2010;7(8). 
10. van Doorslaer E, O‘Donnell O, Rannan-Eliya RP, et al. Effect of payments for health care on 
poverty estimates in 11 countries in Asia: an analysis of household survey data. Lancet. 
2006;368(9544):1357–1364. 
11. Correa-de-Araujo R, Miller GE, Banthin JS, Trinh Y. Gender differences in drug use and 
expenditures in a privately insured population of older adults. J Womens Health (Larchmt). 
2005;14(1):73–81. 
12. Carrasco-Garrido P, Hernández-Barrera V, López de Andrés A, Jiménez-Trujillo I, Jiménez-
García R. Sex-Differences on self-medication in Spain. Pharmacoepidemiol Drug Saf. 2010. 53 
 
Available at: http://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/pubmed/20872823. 
Accessed October 25, 2010. 
13. Zaidi SA. Gender perspectives and quality of care in underdeveloped countries: disease, 
gender and contextuality. Soc Sci Med. 1996;43(5):721–730. 
14. Damanhori A, Al Khaja K, Sequeira RP. Gender-based treatment outcomes in diabetic 
hypertension. J Postgrad Med. 2008;54(4):252–258. 
15. Johansson E, Long NH, Diwan VK, Winkvist A. Gender and tuberculosis control: 
perspectives on health seeking behaviour among men and women in Vietnam. Health Policy. 
2000;52(1):33–51. 
16. Braitstein P, Boulle A, Nash D, et al. Gender and the use of antiretroviral treatment in 
resource-constrained settings: findings from a multicenter collaboration. J Womens Health 
(Larchmt). 2008;17(1):47–55. 
17. Le Coeur S, Collins IJ, Pannetier J, Lelièvre É. Gender and access to HIV testing and 
antiretroviral treatments in Thailand: Why do women have more and earlier access? Social 
Science & Medicine. 2009;69(6):846–853. 
18. Obrist B, Iteba N, Lengeler C, et al. Access to Health Care in Contexts of Livelihood 
Insecurity: A Framework for Analysis and Action. PLoS Med. 2007;4(10):e308. 
19. Ross-Degnan D, et al. Improving Community Use of Medicines in the Management of Child 
Illness: A Guide to Developing Interventions. 2008. 
20. Institute of Medicine. Unequal Treatment: Confronting Racial and Ethnic Disparities in 
Health Care. Washington, D.C. 2003. 
21. Cook BL, McGuire TG, Meara E, Zaslavsky AM. Adjusting for health status in non-linear 
models of health care disparities. Health Services and Outcomes Research Methodology. 
2009;9(1):1–21. 
22. Cook, Benjamin Le, McGuire TG, Lock K, Zaslavsky AM. Comparing Methods of Racial 
and Ethnic Disparities Measurement across Different Settings of Mental Health Care. Health 
Services Research. 2010;45(3):825–847. 
23. World Health Oranization. WHO Operational package for assessing, monitoring and 
evaluating country pharmaceutical situations. Geneva, Switzerland: World Health Organization; 
2007. Available at: http://apps.who.int/medicinedocs/index/assoc/s14877e/s14877e.pdf. 54 
 
24. World Health Oranization. Manual for the Household Survey to Measure Access and Use of 
Medicines. 2008. Available at: 
http://www.who.int/medicines/areas/coordination/household_manual_february_2008.pdf. 
Accessed October 22, 2010. 
25. McGuire TG, Alegria M, Cook BL, Wells KB, Zaslavsky AM. Implementing the Institute of 
Medicine Definition of Disparities: An Application to Mental Health Care. Health Serv Res. 
2006;41(5):1979–2005. 
26. Rosner B. Fundamentals of Biostatistics. 7th ed. Duxbury Press; 2010. 
27. McDonough P, Walters V. Gender and health: reassessing patterns and explanations. Social 
Science & Medicine. 2001;52(4):547–559. 
28. World Health Organization. WHO | Women and health: today‘s evidence tomorrow‘s 
agenda. 2009. Available at: http://www.who.int/gender/women_health_report/en/index.html. 
Accessed October 27, 2010. 
29. Verbrugge LM. Gender and Health: An Update on Hypotheses and Evidence. Journal of 
Health and Social Behavior. 1985;26(3):156–182. 
30. Wagner AK. Medicines need and access: Are there gender inequities. In: Plenary 
presentation. Antalya, Turkey; 2011. 
31. Stephens PN, Ross-Degnan D, Wagner AK. Does Physician Prescribing for Men and Women 
Differ. In: Abstract #954. Antalya, Turkey; 2011. 
32. El Arifeen S, Baqui AH, Victora CG, et al. Sex and socioeconomic differentials in child 
health in rural Bangladesh: findings from a baseline survey for evaluating Integrated 
Management of Childhood Illness. J Health Popul Nutr. 2008;26(1):22–35. 
33. UNICEF. Boys and girls in the life cyle: sex-disaggregated data on a selection of well-being 
indicators, from early childhood to young adulthood. New York: UNICEF; 2011. 
34. Greig A, Kimmel M, Lang J. Men, Masculinities & Development. Gender in Development 
Monograph Series. 2000;10. 
35. Foreman M. AIDS and Men: Taking Risks or Taking Responsibility? Zed Books; 1999. 
36. Collumbien M, Hawkes S. Missing men‘s messages: does the reproductive health approach 
respond to men‘s sexual health needs? Cult Health Sex. 2000;2(2):135–150. 
37. World Bank. Gender Equality and Development. Washington, DC: The World Bank; 2012. 55 
 
38. World  Economic Forum. World Economic Forum - Gender Gap Report. 2010. Available at: 
http://www.weforum.org/en/Communities/Women%20Leaders%20and%20Gender%20Parity/G
enderGapNetwork/index.htm. Accessed October 26, 2010. 
39. Fikree FF, Pasha O. Role of gender in health disparity: the South Asian context. BMJ. 
2004;328(7443):823–826. 
40. Willis JR, Kumar V, Mohanty S, et al. Gender differences in perception and care-seeking for 
illness of newborns in rural Uttar Pradesh, India. J Health Popul Nutr. 2009;27(1):62–71. 
41. Pandey A, Sengupta PG, Mondal SK, et al. Gender differences in healthcare-seeking during 
common illnesses in a rural community of West Bengal, India. J Health Popul Nutr. 
2002;20(4):306–311. 
 
   56 
 
Web Appendix Table 6a: Risk Ratios (95% CI) from multivariable models predicting source of acute care
1  
  Public Hospital 
Private 
Hospital 
Pharmacy or 
drug seller 
NGO, 
mission 
hospital  Other
2 
More than 
one source 
of care  
   (n=470)  (n=311)  (n=462)  (n=180)  (n=45)  (n=321) 
Being female  0.83  1.01  1.06  1.00  0.88  0.95 
   (0.64-1.07)  (0.75-1.38)  (0.81-1.39)  (0.72-1.39)  (0.49-1.56)  (0.73-1.23) 
Very serious 
illness
3 
2.59*  1.83*  0.28*  2.64*  3.43*  2.05* 
(1.85-3.63)  (1.17-2.9)  (0.19-0.41)  (1.55-4.49)  (1.26-9.35)  (1.42-2.95) 
Somewhat 
serious illness
3 
1.38+  1.18  0.44*  1.79*  1.90  1.38+ 
(0.98-1.93)  (0.83-1.67)  (0.32-0.59)  (1.11-2.87)  (0.77-4.71)  (0.97-1.97) 
Being over five 
years of age 
1.18  1.01  1.41*  1.50*  2.15*  1.13 
(0.91-1.53)  (0.77-1.34)  (1.05-1.89)  (1.04-2.17)  (1.02-4.52)  (0.85-1.49) 
Gambia
4  0.07*  0.05*  0.09*  0.34*  0.48  0.33* 
  (0.04-.011)  (0.02-0.13)  (0.05-0.15)  (0.16-0.70)  (0.10-2.35)  (0.20-0.55) 
Kenya
4  0.19*  0.84  0.33*  0.72  1.61  0.45* 
  (0.13-0.29)  (0.44-1.6)  (0.20-0.55)  (0.35-1.47)  (0.36-7.16)  (0.27-0.77) 
Nigeria
4  1.50+  0.85  1.90*  1.34  5.41*  2.55* 
  (0.95-2.37)  (0.42-1.72)  (1.16-3.13)  (0.60-2.97)  (1.26-23.3)  (1.44-4.54) 
Uganda
4  0.10*  0.91  0.18*  0.28*  0.83  0.38* 
  (0.06-0.15)  (0.49-1.67)  (0.11-0.28)  (0.12-0.61)  (0.18-3.88)  (0.22-0.66) 
                    
*p<.05    + p<.10 
 
1 Comparison group in models is public health center or dispensary (n=808) 
2 Other includes traditional healer, friend, and neighbor 
3 Compared to not serious 
4 Compared to Ghana    57 
 
 
*p<.05 
+ p<.10 
1 Comparison group in models is doctor or nurse (n=1,476) 
2 Other includes self, household member, friend, neighbor, traditional healer 
3 Compared to not serious 
4 Compared to Ghana    
Web Appendix Table 6b.  Risk Ratios (95% CI) from multivariable models 
predicting source of obtaining prescriptions for acute conditions
1 
 
Pharmacy or 
drug seller  Other
2 
More than 
one source of 
care  
   (n=319)  (n=284)  (n=96) 
Being female  0.97  1.09  1.09 
   (0.74-1.26)  (0.87-1.36)  (0.72-1.67) 
Very serious acute illness
3  0.20*  0.27*  0.73 
  (0.14-0.29)  (0.19-0.37)  (0.40-1.33) 
Somewhat serious acute illness
3  0.45*  0.47*  0.63+ 
  (0.34-0.59)  (0.36-0.62)  (0.37-1.09) 
Being over five years of age  1.28+  1.06  1.22 
   (0.97-1.68)  (0.84-1.35)  (0.75-1.99) 
Gambia
4  2.21*  43.00*  2.01 
  (1.18-4.15) 
(26.60-
69.46)  (0.75-5.34) 
Kenya
4  0.57*  1.16  0.70 
  (0.34-0.94)  (0.76-1.79)  (0.35-1.39) 
Nigeria
4  1.71*  2.03*  1.69 
  (1.09-2.71)  (1.37-3.01)  (0.84-3.42) 
Uganda
4  0.49*  0.80  0.47* 
  (0.29-0.81)  (0.51-1.28)  (0.22-1.00) 58 
 
 
   Web Appendix Table 6c.  Risk Ratios (95% CI) from multivariable models 
predicting source of obtaining medicines for acute conditions
1 
 
Public 
Health 
Center 
Public 
Hosp 
NGO, Mission 
Hospital  Other
2 
More than 
one source 
of care  
  (n=824)  (n=398)  (n=202)  (n=106)  (n=200) 
Being female  1.02  0.86  0.90  0.88  0.99 
   (0.81-1.29)  (0.66-1.12)  (0.63-1.23)  (0.55-1.41)  (0.73-1.34) 
Very serious acute 
illness
3  1.42*  3.31*  3.32*  1.36  2.56* 
  (1.06-1.89)  (2.36-4.65)  (1.95-5.67)  (0.75-2.46)  (1.58-4.18) 
Somewhat serious acute 
illness
3  1.55*  1.86*  2.12*  1.14  1.45+ 
  (1.19-2.02)  (1.35-2.56)  (1.42-3.16)  (0.73-1.79)  (0.95-2.19) 
Being over five years of 
age  0.73*  0.90  0.95  0.81  0.84 
   (0.57-0.93)  (0.69-1.53)  (0.67-1.33)  (0.55-1.19)  (0.59-1.18) 
Gambia
4  11.36*  1.00  3.17*  0.97  2.79* 
  (7.11-18.16)  (0.66-1.53)  (1.80-5.61)  (0.39-2.38)  (1.56-4.98) 
Kenya
4  1.45  0.26*  0.88  0.83  0.88 
  (0.93-2.27)  (0.16-0.42)  (0.52-1.47)  (0.42-1.65)  (0.50-1.54) 
Nigeria
4  0.35*  0.81  0.52*  0.71  0.95 
  (0.21-0.58)  (0.55-1.18)  (0.30-0.88)  (0.34-1.48)  (0.55-1.64) 
Uganda
4  2.09*  0.23*  0.62  0.67  0.71 
  (1.40-3.12)  (0.14-0.37)  (0.34-1.11)  (0.34-1.33)  (0.40-1.26) 
                 
    
*p<.05 
+ p<.10 
 
1 Comparison group in models is private provider, pharmacy, or drug seller (n=934) 
 2 Other includes home, friend, neighbor, and traditional healer 
3 Compared to not serious 
4 Compared to Ghana 
   59 
 
 
 
 
 
 
 
 
 
 
 
 
----Page intentionally left blank---- 
   60 
 
 
 
 
 
 
 
Chapter 3: 
 
Disparities in quality and outcomes of care for patients with type 2 
diabetes in Mexico City: 
Assessment of the impact of patient education using propensity 
score matching
e 
 
   
                                                       
e This chapter is co-authored by Svetlana Duobova, Alan M. Zaslavsky, Joshua A. Salomon, Dennis 
RossDegnan, Ricardo Peres-Cuevas and Anita K. Wagner 
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Abstract 
Background 
Disparities in quality and outcomes of healthcare could be due to differences in patient 
educational attainment. Propensity score matching, allows us to more appropriately account for 
disparities compared to traditional unmatched regression based risk adjustments. 
Methods 
Our sample included patients with type 2 diabetes who were older than 19 years of age and 
visited two family medicine clinics in Mexico City at least once in 2009 (n=13,855). The 
predictor variable of interest was education, categorized into three levels: illiterate and primary 
school (n=4,575); secondary and high school (n=3,856); undergraduate and postgraduate training 
(n=1,402). Outcomes were eleven indicators of processes of care and five indicators of clinical 
outcomes, defined based on existing guidelines for diabetes care. Adjusted differences between 
education and outcomes were calculated using Mahalanobis matching with calipers defined by 
propensity score and bootstrapped variances. 
Results 
Unadjusted outcomes showed patients with higher education had better clinical outcome 
indicators than those with lower education. Propensity score matched estimates showed few 
significant differences in processes and outcomes of care, although the direction of estimates 
tended to indicate those with lower educational levels had better processes of care. The 62 
 
unmatched regression based risk adjustments overestimated the significance and magnitude of 
the association. 
Conclusions 
Disparities by education on processes and outcomes of care are few when estimated based on 
propensity score methods and may be overestimated by unmatched regression methods. 
Characteristics other than education may be more important for targeting of programs to improve 
healthcare. 
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Introduction 
Understanding how disparities in healthcare processes may be associated with education is 
important to target interventions to improve quality of care and outcomes. However, it is 
challenging to determine the degree to which better education contributes directly to better health 
care and health; other factors associated with education and health care may also be important 
determinants of their relationship to health status (Figure 5).
1–6  
Education is one of the most stable indicators of socio economic status as it remains constant 
over a lifetime. Differences in health care by educational attainment do not necessarily imply 
disparities. As framed by the Institute of Medicine (IOM), disparities in health care can be 
defined as unfair differences in treatment which are not justified by underlying health conditions 
or treatment preferences.
7 For example, differences in health care due to discrimination or the 
operation of the health system would constitute a disparity, while differences due to health care 
needs would not. 
7,8,9 To disentangle disparities due to education we would need to appropriately 
control for differences in clinical need due to comorbidities, age and sex, but not differences in 
health care due to socio-economic factors like income and class since these may be co-
determinant.
10  
A number of mechanisms have been proposed to explain the relationship between education and 
health care and the proposed disparities analysis identifies the sum of these pathways that are the 
responsibility of the health care system. Higher education is associated with more desirable 
behaviors including earlier symptom recognition, more timely care seeking, and better adherence 
to medicines.
11–13 It is also linked to a range of health promoting behaviors and environments, 
including better insurance coverage, better access to health facilities, better diet, more exercise, 64 
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Figure 5: Conceptual relationship between education and health care, highlighting the clinical need variables 
which are controlled for and socio economic factors not controlled for in estimating disparities 
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and lower prevalence of conditions such as hypertension, dyslipidemia, and other cardiovascular 
diseases.
1,13–16 
In the US, race and education tend to be associated. Studies have found that when providers have 
ethno-linguistic concordancy with more highly educated patients, they may be more attentive 
and provide better quality of care.
17,18 In addition, demographic factors such as age, marital 
status, race, and sex may confound the association between education and health.
19 Younger age 
cohorts may have higher education due to changing social norms and may be healthier due to 
their younger age.  Women may be less likely to be educated, but may be healthier than men of 
the same age due to biological factors.   
In the treatment of chronic diseases, such as diabetes, the link between education and quality of 
care is especially important. Diabetes affects 285 million adults worldwide, and is projected to 
increase by 69 percent in developing countries and 20 per cent in developed countries over the 
next twenty years.
20Appropriate management of the disease depends in part on clinicians 
performing recommended processes of care to achieve desired clinical outcomes. Among 
patients with diabetes, higher education is found to be significantly associated with higher rates 
of diagnosis and treatment, in Asian and European countries.
 5, 21–23,24,25,16 
Most existing studies have assessed the effects of education on diabetes care using self-reported 
outcomes
24,25 Self-reported health outcomes are subject to recall biases which could be linked to 
education status.
26 In addition, disparities between health care and education are usually 
explained using unmatched regression based risk adjustments. These adjustments impose 
distributional assumptions on the data and, in particular, assume that groups with different 66 
 
educational attainments have similar distributions of other socio-demographic factors like age, 
sex, marital status. The functional form of the regression extrapolates beyond the area of overlap 
creating an illusion of common support. Quasi-experimental methods, such as propensity score 
matching, allows us to more appropriately compare differences in health care. The propensity 
score reduces the collection of measured potential confounding characteristics to a single 
composite characteristic on which balance between groups can be achieved via matching.
27  
We tested the effects of education on health care processes and outcomes among a propensity 
score matched sample of patients with diabetes who had the same social insurance in Mexico 
City. They were similar in terms of disease, insurance coverage, and ethno-linguistic factors 
(patients and providers were native Spanish speakers). To assess potential disparities in care due 
to patient education, we operationalized the IOM framework and matched patients on indicators 
of health need. We used laboratory test results as measures of intermediate health outcomes. 
These methods allowed us to answer two questions. First, does higher education lead to better 
processes and outcomes of care in this context, controlling for appropriate need and preferences? 
Second, how do traditional regression-based risk adjustments compare with propensity score 
matching in terms of the magnitude and significance of estimated education effects? 
Methods 
Setting 
The study was conducted at the Mexican Social Security Institute (IMSS). IMSS, through a 
system of health centers and hospitals, provides services to approximately 48 million people who 
represent about 47 percent of the Mexican population, mainly workers in the formal sector and 
their families. The IMSS network includes 13,983 family medicine doctors (primary care 67 
 
providers), 19,848 specialists, 1,516 primary health clinics, 240 hospitals and 680 pharmacies 
across Mexico. Many clinics also have laboratory facilities. 
Each IMSS subscriber and his or her family is assigned to a family medical clinic based on 
residential location.  Primary care providers in family medicine clinics provide referrals to 
secondary and tertiary care facilities within the IMSS network. Subscribers and their family 
members receive the same benefits. In 2003, IMSS began implementation of an electronic 
medical record (EMR) in clinics in Mexico City.  The VISTA-based
28 EMR includes information 
on patient demographic and clinical characteristics, and care received at each visit. A dedicated 
diabetes module in the EMR is intended to capture information on diabetes specific processes of 
care. EMR data can be linked with other IMSS databases containing patient-specific information 
on laboratory results.  
Sample and Data 
The study sample consists of 13,855 patients who were older than 19 years of age who visited 
two family medicine clinics in Mexico City at least once between January 1
st and December 31
st 
2009 and had an ICD-10 diagnosis of type 2 diabetes (T2D) noted in the EMR (E111-E119, 
E140-E149 and E14X). For these patients, we extracted all EMR and laboratory.  We assessed 
the data for completeness, consistency, and validity (described elsewhere). 
29 
Measures 
Patient education 
Our main predictor variable of interest is education, categorized into three levels: illiterate and 
primary school (n=4,575); secondary and high school (n=3,856); and undergraduate and 68 
 
postgraduate (n=1,402). Other educational attainments and missing data were classified as 
missing (n=4,022).  Since increasing educational attainments may have distinct effects on quality 
of care and clinical outcomes, we created two subgroups: primary versus secondary education in 
a subgroup including only those individuals and secondary versus tertiary in a second 
subgroup.
22,27 Each subgroup included an indicator variable contrasting the higher education 
status with lower education status. 
Demographic and clinical patient characteristics 
We characterized patients according to age (continuous measure in years); sex; marital status 
(binary variable for married vs. single, divorced, widowed, or in partnership); comorbidities 
(three indicator variables if had hypertensive disease, dyslipidemia, or other cardio vascular 
diseases); and fixed effects for clinic (as clinics differed in staffing levels and arrangements for 
conducting laboratory tests). 
To characterize severity of illness, we included measures of last total cholesterol (mg/dl), 
average body mass index (BMI) between first and last reading (kg/m
2), highest fasting glucose 
level (mg/dl), highest systolic and highest diastolic blood pressure (mmHg) during the three most 
recent encounters.  There is considerable debate whether an average or highest measure of blood 
glucose and blood pressure best reflect diabetes control status.
30–32 The highest values may better 
capture severity of disease since even one uncontrolled measurement could indicate a period of 
poor control and subsequent risk of complications. BMI is considered to be more stable over the 
course of a year and so we used the average between the first and last measure of BMI during the 
study period.
33  
Quality of care outcome indicators 69 
 
We used eleven indicators of processes of care and five indicators of clinical outcomes of care. 
These were based on existing guidelines for diabetes care by National Institute for Clinical 
Excellence (NICE),
34 American Diabetic Association (ADA),
35 and Health Care Effectiveness 
Data and Information Set (HEDIS)
36 and adapted to the Mexican context by local members of 
the study team.
29  
Process of care indicators 
Process of care indicators included: number of visits with a physician in the primary care clinic; 
whether a patient had at least three measurements of fasting blood glucose and blood pressure; 
whether a patient had an order for a comprehensive foot exam; a glucose test; a cholesterol test 
(if the patient did not have a previous diagnosis of dyslipidemia); and whether the patient was 
prescribed metformin (if overweight and no documented contraindications); an angiotensin 
converting enzyme (ACE) inhibitor (if hypertensive and no documented contraindications); 
aspirin (if above 40 years old with history of smoking, hypertension or dyslipidemia and no 
documented contraindications); or a statin (if cholesterol measurement greater than 200mg/dl 
and no documented contraindications.
6 
Outcome of care indicators 
                                                       
6 Contraindications to metformin: renal failure,  respiratory or advanced liver failure, congestive heart failure, 
coronary artery disease or advanced atherosclerosis, pregnancy, intolerance to metformin; contraindications to 
inhibitors of angiotensin converting enzyme: intolerance and/or prior treatment failure;,  contraindications to 
acetylsalicylic acid in doses of 75-150mg/day: history of hypersensitivity to aspirin, peptic ulcer disease, and 
hemophilia; contraindications to statins: hypersensitivity to any component of the drug, active liver disease or 
unexplained persistent elevations of serum transaminases, pregnancy and lactation.
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Indicators of care outcomes were binary measures of glucose levels less than or equal to 
130mg/dl in each of the last three measurements; most recent total cholesterol reading under 
200mg/dl; systolic blood pressure less than 130mmHg and diastolic pressure less than 80 mmHg 
in each of the most recent three measurements; and presence of no diabetic complications 
(diabetic retinopathy, neuropathy, nephropathy, or peripheral vascular disease). 
Statistical analysis  
The unit of analysis was the individual. We described demographic and clinical characteristics 
and indicators of process and outcome quality by educational attainment. We tested education 
differences using Pearson‘s chi square test of independence for binary variables and a one way 
ANOVA for difference of means for continuous variables. We explored unadjusted differences 
between educational attainment and the 16 process and outcome indicators.  
Propensity score matching 
Adjusted differences between education and outcomes were calculated using Mahalanobis 
matching with calipers defined by propensity score.
37–40 This matching algorithm has been 
shown to be a robust method to achieve covariate balance.
37  For ease of interpretation, we 
contrasted primary education versus with secondary education only; and secondary education 
versus tertiary education only (dropping missing observations for this stage of the analysis). 
Comparing primary education versus tertiary education was not suitable as patients differed 
significantly on most variables and there was little overlap of these patient groups. 
First, we predicted the propensity score or probability of having attained a higher educational 
attainment using demographic variables, comorbidities and clinic fixed effects. The final model 71 
 
included age as linear and quadratic terms to better capture the non-linear association between 
age and education. The logit function of this predicted probability is considered the propensity 
score. 
27 We plotted the kernel density of the propensity score for those with a primary education 
and those with a secondary education. The two kernel densities showed a large amount of 
overlap indicating significant potential for matches (see Web Appendix Figure 7). This is 
because a person with primary and a person with secondary education who have the same 
propensity score are essentially viewed as comparable, even though they may differ on values of 
specific covariates.
40 We repeated this for tertiary education versus secondary education. 
Next, we used nearest available Mahalanobis matching with replacement and within calipers 
defined by 0.25 times the standard error of the propensity score to create matched samples which 
were balanced on age, sex, marital status, comorbidities and clinic, but differed in terms of actual 
educational attainment and other differences such as income, class etc. We determined balance 
of matching covariates through t-tests of difference of proportions and subsequent change in 
bias. 
Finally, to evaluate the magnitude and significance of the relationship between education and 
each outcome, we calculated the percentage point difference in the full matched sample for 
higher versus lower educational attainment.  The average effect was calculated from the full 
sample match. The variance was calculated through a process of bootstrapping. A thousand 
random samples of the original distributions were chosen with replacement and the propensity 
score, matching algorithm, and effect were re-estimated. This resulted in a distribution of effect 
estimates, which was approximately normal. The 2.5
th and 97.5
th percentile values of this 
distribution were used to construct 95 per cent confidence intervals.
41 72 
 
We used Stata 12.0 (Texas, Stata Corp) for all analyses; and the psmatch2 and pstest suite of 
commands for matching.
42  We considered p <0.05 as statistically significant. 
Sensitivity analyses 
Unmatched regression based risk adjustments versus propensity score methods 
To answer our second question, we compared the magnitude and significance of estimates from 
propensity score matched results to unmatched regression based risk adjustment.  For binary 
outcomes, we used logistic regression models to estimate associations between education 
(conducted pair wise) and outcomes, controlling for matching variables (demographic, 
comorbidities, and clinic fixed effects). For outcomes which were only relevant to a specific 
group, eg prescribed metformin if obese, we only performed the regression on the relevant group 
(here only on obese). 
Other Sensitivity based analyses 
We conducted sensitivity analyses to test the specifications of our models. We explored different 
regression models to best predict the propensity score and compared the goodness of fit and 
balance of each model. We also calculated approximate standard errors versus bootstrapped 
standard errors; and 100 bootstrapped iterations versus 500 or 1000 runs.  
The Harvard Pilgrim Health Care Human Studies Committee and the IMSS Research Ethical 
Committee of the IMSS Research Review Board approved this study. 
Results 
Characteristics of the study population 73 
 
Patients with diabetes with different educational attainments differed in terms of demographic 
and clinical characteristics. Patients who were illiterate or had primary school education were 
significantly more likely to be unmarried older women who visited clinic one. They were also 
more likely to have hypertension and less likely to have cardio vascular disease or dyslipidemia 
than patients with secondary or tertiary educational attainment (Table 7).  
Of the total population, 4,022 had data missing on educational attainment and so were dropped 
from the calculation of effect estimates. This missing population tended to be more similar to the 
secondary school education group in terms of demographic characteristics and clinical indicators. 
On matching on select covariates the percent change in bias ranged from 89.5 to 100.0 percent. 
In the full matched sample, this was achieved by dropping 137 (1.7 per cent) secondary 
education observations in the primary versus secondary comparison and 26 (0.5 per cent) tertiary 
education observations in the tertiary versus secondary observations. 
Unadjusted outcomes disaggregated by education and sex 
Process of care indicators differed by patient educational attainment. Physicians were more 
likely to order diagnostic tests (comprehensive foot exams, ophthalmologist referrals and glucose 
tests) for patients who were illiterate or had primary schooling than for patients with higher 
education (secondary or tertiary education). They were less likely to prescribe metformin for 
obese patients with lower educational attainment but there were no significant differences in 
prescribing of aspirin, statins, and ACE inhibitors (Table 8).  
Conversely, patients with higher education had better clinical outcome indicators than those with 
lower education. Patients with an undergraduate or graduate degree were significantly more  74 
 
Table 7: Descriptive characteristics of sample by education status 
  
Illiterate/ 
Primary School 
Secondary/ 
High School 
Undergraduate
/ 
Postgraduate 
Education 
Status 
Missing 
p-value 
   (n= 4,575)  (n=3,856)  (n=1,402)  (n=4,022)   
Demographic characteristics                
Male (%)  30.4   40.1  68.8  45.7  0.0000 
Age (mean, years)  67.8  61.2  61.5  62.0  0.0000 
Married (%)  52.8  60.7  69.2  .  0.0000 
In Clinic 2 (%)  36.6  50.3  59.1  55.5  0.0000 
           
Clinical characteristics                
Hypertension (%)  74.8  68.4  68.8  51.2  0.0000 
Dyslipidemia (%)  47.0  53.8  53.9  37.5  0.0000 
Other cardio vascular disease (%)  12.9  11.7  15.8  10.7  0.0000 
                
Total cholesterol level (mean, 
mg/dl) 
200.6  201.7  197.9  201.7  0.0833 
Average body mass index of two 
readings (mean, kg/m2) 
29.2  29.5  28.9  29.0  0.0000 
Highest fasting blood glucose of 
three readings (mean, mg/dl) 
181.7  175.8  167.7  178.8  0.0000 
Highest systolic blood pressure of 
three readings (mean, mmHg) 
131.7  129.6  129.8  128.2  0.0000 
Highest diastolic blood mean, 
pressure of three readings (mmHg) 
81.1  81.1  81.0  80.1  0.0414 
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Table 8: Unadjusted associations between education and quality of care * 
  
Illiterate/ 
Primary 
School 
Secondary/ 
High School 
Undergraduate/ 
Undergrad/Postgraduate 
Missing 
   (n=4,575)  (n=3,856)  (n=1,402)  (n=4,022) 
Processes of Care 
       
1. Number of visits with 
family doctor in 2009 
(mean) 
9.9  9.96  9.56  7.0 
   [9.78;10.01]  [9.80;10.11]  [9.33;9.79]  [6.85;7.15] 
2. Comprehensive foot exam   5.9  5.5  5.2  0.01 
   [0.58;0.61]  [0.53;0.56]  [0.50;0.55]  [0.01;0.01] 
3. Referral to 
ophthalmologist  
0.22  0.2  0.18  0.13 
   [0.21;0.23]  [0.19;0.21]  [0.16;0.20]  [0.12;0.14] 
4. Glucose test ordered  0.78  0.74  0.68  0.62 
   [0.77;0.79]  [0.73;0.76]  [0.66;0.71]  [0.60;0.63] 
5. At least 3 glucose 
measurements 
0.5  0.42  0.37  0.24 
   [0.49;0.52]  [0.40;0.43]  [0.34;0.39]  [0.23;0.26] 
6. At least 3 blood pressure 
measurements 
0.94  0.93  0.91  0.73 
   [0.93;0.95]  [0.92;0.94]  [0.90;0.93]  [0.71;0.74] 
7. Cholesterol measurement 
among patients‘ with  
dyslipidemia  
0.68  0.65  0.62  0.49 
   [0.66;0.70]  [0.62;0.67]  [0.58;0.66]  [0.47;0.51] 76 
 
  
Illiterate/ 
Primary 
School 
Secondary/ 
High School 
Undergraduate/ 
Undergrad/Postgraduate 
Missing 
   (n=4,575)  (n=3,856)  (n=1,402)  (n=4,022) 
8.Metformin prescribed 
among overweight patients 
without contraindications 
0.58  0.64  0.65  0.56 
   [0.57;0.60]  [0.62;0.66]  [0.62;0.68]  [0.54;0.58] 
9. ACEI prescribed among 
patients with hypertension 
without contraindications 
0.55  0.54  0.53  0.56 
   [0.54;0.57]  [0.52;0.56]  [0.50;0.57]  [0.54;0.58] 
10. Aspirin prescribed 
among patients over 40 
years with risk factors and 
without contraindications 
0.42  0.37  0.40  0.36 
   [0.41;0.44]  [0.36;0.39]  [0.37;0.43]  [0.34;0.37] 
11. Statins prescribed among 
patients with total 
cholesterol > 200mg/dl  and 
without contraindications 
0.5  0.51  0.53  0.48 
 Clinical Outcomes  [0.48;0.52]  [0.49;0.54]  [0.49;0.58]  [0.45;0.51] 
12. Glucose < 130mg/dl in 
each of last three 
measurements 
0.19  0.21  0.25  0.22 
   [0.17;0.20]  [0.19;0.23]  [0.22;0.29]  [0.20;0.25] 
13. Total cholesterol < 
200mg/dl 
0.52  0.51  0.56  0.52 
   [0.50;0.54]  [0.49;0.53]  [0.53;0.59]  [0.50;0.54] 
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Illiterate/ 
Primary 
School 
Secondary/ 
High School 
Undergraduate/ 
Undergrad/Postgraduate 
Missing 
   (n=4,575)  (n=3,856)  (n=1,402)  (n=4,022) 
14. Systolic pressure < 
130mmHg  in each of last 
three measurements 
0.38  0.42  0.40  0.48 
   [0.36;0.39]  [0.41;0.44]  [0.37;0.43]  [0.46;0.50] 
15. Diastolic pressure less 
than 80mmHg in each of last 
three measurements 
0.14  0.13  0.12  0.13 
   [0.13;0.15]  [0.12;0.14]  [0.11;0.14]  [0.12;0.14] 
16. No diabetic 
complications± 
0.65  0.70  0.73  0.76 
   [0.64;0.66]  [0.69;0.72]  [0.70;0.75]  [0.74;0.77] 
95% Confidence intervals in 
parentheses         
 
*Unless otherwise noted, all entries represent proportions of patients having the respective indicator; ± Diabetic 
complications are defined as having an ICD-10 code for diabetic retinopathy, neuropathy, nephropathy, or peripheral vascular 
disease during the study period.  ACEI= angiotensin converting enzyme inhibitor 
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likely to have glucose levels under 130mg/dl and less likely to have a diabetes-related 
complication than patients who were illiterate or had primary schooling. There were no 
significant differences between male and females for most outcomes within the same educational 
attainment (Web Appendix Table 10).  
Adjusted associations based on propensity-score matched sample 
Processes of care 
For the estimates derived from the propensity score matched samples, there were few significant 
differences in process of care indicators between patients with different education levels, 
although the direction of estimates tended to indicate those with lower educational levels had 
better processes of care (Table 9a). For example, patients with no or primary school education 
were 7.6 (4.1, 12.1) percentage points more likely to have three glucose measurements than 
patients with secondary or high school education. Similarly patients with secondary or high 
school education were 4.8 (0.6, 10.2) percentage points more likely to have a glucose test 
ordered than patients with undergraduate or postgraduate education. Even though not significant, 
primary physicians tended to order more diagnostics for those with a lower education level than 
a higher education level including ordering more foot exams, taking at least three measures of 
glucose blood pressure, and referring to an ophthalmologist. 
Clinical outcomes of care 
There were few significant differences in outcomes of care by educational attainment, although 
the direction of effects indicated patients with higher education tended to have better outcomes. 79 
 
Patients with an undergraduate or post graduate education were 7.4 (1.8, 12.4) percentage points 
less likely to have complications due to diabetes than patients with a secondary or high school 
degree. 
Sensitivity Analyses 
The most predictive model for propensity score included the non linear effects of age as a 
squared term but did not include interaction terms of age and sex. The approximate standard 
errors were narrower than the bootstrapped standard errors. This is because the approximate 
standard errors impose a number of assumptions-- independent observations, homoskedasticity 
of the outcome variable within different education levels and variance of the outcome does not 
depend on the propensity score.
42  It also does not take into account that the propensity score is 
estimated.100 bootstrapped iterations were less stable than 500 iterations, but there was little 
difference between 500 and 1000 iterations. 
Unmatched regression-adjusted estimates showed a greater number of outcomes with significant 
differences by educational attainment than propensity score matching (Table 9b). Of the 32 
outcomes studied (16 outcomes each for two subgroups), the unmatched regression risk adjusted 
estimates showed education to have a significant effect on ten versus four outcomes using 
propensity scores. When we compared the size of the effect estimates between the two methods, 
9 of the 32 outcomes had significantly different effect sizes if calculated by regression risk 
adjustment as opposed to propensity scores (Figure 6). In most cases the (5/9) the propensity 
score estimate was closer to the null and the unmatched regression estimate tended to be higher. 
The bootstrapped confidence intervals around the propensity score estimate tended to be much 80 
 
wider than those around the regression estimates, possible because the propensity score method 
was accounting for more uncertainty. 
Discussion  
In this population of patients with diabetes in Mexico City we find few disparities due to 
education in the processes and outcomes of care received in models using propensity adjusted 
estimates and a greater number of disparities using traditional estimation methods. These 
findings are unique, both from methodological and a policy perspective. To our knowledge, this 
is the first study to apply a robust quasi-experimental technique like Mahanolobian matching  
   81 
 
 
Table 9a: Differences in processes and outcomes of care based on propensity score matched adjusted models 
  
Secondary or High School - 
Illiterate or Primary School 
Undergraduate or Post Graduate - 
Secondary or High School 
Absolute Difference [95% CI] 
(n=8,228)  
Absolute Difference [95% CI] 
(n=5,114) 
Processes of Care       
1. Number of visits with family doctor in 
2009 (mean) 
0.18 [- 0.17, 0.45]  -0.70 [-1.09, -0.05]** 
Absolute difference (percentage point)  (percentage points)  (percentage points) 
2. Comprehensive foot exam   -3.27 [-7.28, 0.20]*  -0.75 [-5.45, 4.82] 
3. Referral to ophthalmologist   -0.61 [-1.88, 4.12]  -1.12 [-6.25, 2.31] 
4. Glucose test ordered  -0.86 [-4.75, 1.85]  -4.78 [-10.21, -0.58]** 
5. At least 3 glucose measurements  -7.64 [-12.09, -4.08]**  -2.69 [-8.49, 1.43] 
6. At least 3 blood pressure measurements  -0.64 [-1.83, 1.64]  -1.94 [-4.38, 1.14] 
7. Cholesterol measurement among patients‘ 
with  dyslipidemia  
0.06 [-7.58, 2.17]  0 [-10.22, 3.75] 
8.Metformin prescribed among overweight 
patients without contraindications 
-0.89 [ -4.22, 4.68]  3.92 [ -2.21, 7.64] 
9. ACEI prescribed among patients with 
hypertension without contraindications 
-4.03 [ -7.92, 1.71]  -3.31 [-10.43, 3.01] 
10. Aspirin prescribed among patients over 
40 years with risk factors and without 
contraindications 
-0.39 [-5.52, 2.78]  0.76 [-4.42, 6.99] 
11. Statins prescribed among patients with 
total cholesterol > 200mg/dl  and without 
contraindications 
3.74 [ -4.05, 7.17]  2.91 [-5.54, 11.67] 
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Clinical Outcomes 
Illiterate or Primary School vs  
Secondary or High School 
Undergraduate or Post Graduate 
vs. Secondary or High School 
Absolute Difference [95% CI]  Absolute Difference [95% CI] 
(percentage points)  (percentage points) 
12. Glucose < 130mg/dl in each of last three 
measurements 
1.23 [-0.90, 7.63]  4.20 [-2.17, 12.56] 
13. Total cholesterol < 200mg/dl  0.71 [-3.77, 4.97]  2.50 [-3.06, 8.90] 
14. Systolic pressure < 130mmHg  in each of 
last three measurements 
1.45 [-2.61, 5.26]  -1.31 [-6.54, 4.21 ] 
15. Diastolic pressure less than 80mmHg in 
each of last three measurements  -0.27 [-2.99, 2.50] 
1.23 [-3.18, 4.63] 
16. No diabetic complications±  1.74 [-0.79, 6.63]   7.40 [1.78, 12.39]** 
 
# Results are presented as the average value for patients with higher educational attainment minus average value for 
patients with lower educational attainment (95% Confidence Interval based on 1000 bootstrap iterations); unless 
otherwise noted, entries represent absolute percentage point differences 
± Diabetic complications are defined as having an ICD-10 code for diabetic retinopathy, neuropathy, nephropathy, 
or peripheral vascular disease; * significant at p<0.10; ** significant at p<0.05 
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Table 9b:  Differences in processes and outcomes of care based on unmatched regression based risk adjustments 
  
Secondary or High School - 
Illiterate or Primary School 
Undergraduate or Post Graduate - 
Secondary or High School 
Absolute Difference [95% CI] 
(n=8,228)  
Absolute Difference [95% CI] 
(n=5,114) 
Processes of Care       
1. Number of visits with family doctor in 2009 
(mean) 
0.10[- 0.09, 0.29]  -0.55 [-0.84, -0.26]** 
Percentage point change: Absolute 
difference 
(percentage points)  (percentage points) 
2. Comprehensive foot exam   -3.15 [-5.32, -0.98]**  0.07 [-2.98, 3.13] 
3. Referral to ophthalmologist   0.76[-1.11, 2.63]  -1.26 [-3.80, 1.20] 
4. Glucose test ordered  -2.62 [-4.53, -0.71]**  -5.18 [-7.99, -2.36]** 
5. At least 3 glucose measurements  -8.61 [-10.85, -6.38]**  2.77 [-5.86, 0.31]* 
6. At least 3 blood pressure measurements  -0.25 [-1.34, 0.83 ]  -2.11 [ -3.72, -0.49]** 
7. Cholesterol measurement among patients‘ 
with  dyslipidemia  
-2.64 [-5.71, 0.42]*  -1.96 [-6.49, 2.57] 
8.Metformin prescribed among overweight 
patients without contraindications 
-0.28[-2.83, 2.27]  1.64 [ -2.00, 5.29] 
9. ACEI prescribed among patients with 
hypertension without contraindications 
-3.82 [ -6.48, -1.15]**  -3.26 [-7.10, 0.58]* 
10. Aspirin prescribed among patients over 40 
years with risk factors and without 
contraindications 
-1.65 [-4.07, 0.78]  1.64 [-1.85, 5.13] 
11. Statins prescribed among patients with 
total cholesterol > 200mg/dl  and without 
contraindications 
0.82 [ -2.83, 4.48]  2.45 [-2.96, 7.85] 
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Clinical Outcomes 
 
12. Glucose < 130mg/dl in each of last three 
measurements 
Illiterate or Primary School vs  
Secondary or High School 
Undergraduate or Post Graduate 
vs. Secondary or High School 
Absolute Difference [95% CI]  Absolute Difference [95% CI] 
(percentage points)  (percentage points) 
13. Total cholesterol < 200mg/dl  3.54 [0.83, 6.26]**  3.55 [-0.71, 7.82] 
14. Systolic pressure < 130mmHg  in each of 
last three measurements 
0.38 [-2.25, 3.01]  2.09 [-1.66, 5.85] 
15. Diastolic pressure less than 80mmHg in 
each of last three measurements 
1.35 [-0.88, 3.58]  -1.60 [ -4.77, 1.58] 
16. No diabetic complications±  0.19 [-1.40, 1.77]  0.98 [-1.23, 3.18] 
 
3.39 [1.25, 5.52]**  5.74 [2.84, 8.64]** 
 
# Results are presented as the average value for patients with higher educational attainment minus average value for 
patients with lower educational attainment (95% Confidence Interval based on 1000 bootstrap iterations); unless 
otherwise noted, entries represent absolute percentage point differences 
± Diabetic complications are defined as having an ICD-10 code for diabetic retinopathy, neuropathy, nephropathy, 
or peripheral vascular disease; * significant at p<0.10; ** significant at p<0.05 
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Fig 6: Comparing Estimates. Propensity score matched versus unmatched regression risk 
adjusted estimates. When propensity score and regression effect estimates are the same they fall 
on the 45
o line  
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b. Tertiary Education- Secondary Education 86 
 
with calipers defined by propensity scores to better explore the relationship between education 
and health care. 
From the methodological perspective, we show that unmatched regression based estimates may 
tend to overestimate the magnitude and significance of the effect of education on processes and 
clinical outcomes of care as compared to propensity score matched methods. Through the 
matching process we dropped individuals who had similar levels of education, but very different 
health needs (as captured by demographic and clinical variables), making them not suitable to be 
compared. Assuming common support through use of regression methods may have produced 
biased estimates.   
From a policy perspective, our results suggest that when appropriately adjusted for, education is 
associated with very few significant differences in processes of care and clinical outcomes. 
Patients with lower educational attainment had only one notably worse outcome: patients with a 
university education tended to have fewer complications from diabetes than patients with 
secondary or high school education.  Although not always significant, more patients with lower 
education received interventions we had defined as quality processes of care, and fewer had the 
desired care outcomes, compared to patients with higher education.  
However, the study is subject to key limitations. There were substantial problems in the 
completeness and accuracy of the data in the electronic medical record noted during the course 
of the study. The study team attempted to minimize this source of error through extensive quality 
checking.
29  To the extent that these errors are distributed randomly across patients with different 
educational levels, the consequence would be to bias the education effect sizes toward the null.  87 
 
The external validity of our study may be limited because we chose a sample of patients who 
received care at two purposively selected clinics in Mexico City. This setting may be unique in 
that the population was homogenous in terms of insurance status, benefits provided, and ethno-
linguistic concordance between patients and providers, a reason it was selected. The sample of 
patients dropped from our analyses due to missing data on educational level, tended to have 
similar demographic and clinical values as those with a secondary education (where data was 
available). If we had less missing data for each person we could have imputed the data and 
performed a sensitivity analysis, but as such we had to perform casewise deletion. As physicians 
get more used to the EMR, data entry and extraction should improve to reduce missing data. 
Future research should repeat our analyses across a wider variety of IMSS clinics in Mexico.  
The variance of the propensity score estimates could be subject to bias. The estimated variance 
of the treatment effect includes three sources of uncertainty due to derivation of the propensity 
score, determination of common support, and the order in which treated individuals are 
matched.
43 There is no agreed-upon method to capture these sources of uncertainty, with 
bootstrapping being one method that has been suggested;
44,45however, formal justification for 
bootstrap estimators is limited.
46 Since the estimators are asymptotically linear and our outcomes 
are binary, we believe that bootstrapping has likely led to valid standard errors and confidence 
intervals.
47 The standard errors of the bootstrap estimates are large, and future research should 
focus on ways to produce tighter confidence bounds. 
Conclusion 
We examined education as a predictor of disparities in quality of care for diabetic patients in 
Mexico using traditional and propensity-score matched estimation methods. In a setting where 88 
 
the population is homogenous in terms of insurance coverage, locations of care, and ethno-
linguistic concordance, we show that effects of education on processes and outcomes of care are 
few when estimated based on propensity score methods and may be overestimated by unmatched 
regression methods.  
Low and middle-income countries like Mexico have a rapidly rising burden of chronic illnesses, 
placing strains on national health systems and quality of care.
48 Studies in these settings show 
that the burden of chronic disease is unequally distributed and disproportionately falls on those in 
the lower social economic strata.
49,50 It is important to understand the role of education in 
influencing quality of care in these contexts. Our results suggest that characteristics other than 
education may be more important for identifying patients in need of targeted interventions to 
improve quality of care and outcomes.   
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Web Appendix Fig 7: Propensity score estimation: Large amount of overlap shows significant 
common support region, which is indicative of a high likelihood of matches between both 
groups. 
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Web Appendix Table 10: Unadjusted associations between education and outcomes, disaggregated by gender  
  Male  Female 
  
Illiterate/ 
Primary 
School 
Secondary/ 
High 
School 
Undergrad
/Post Grad 
Missing 
Illiterate/ 
Primary 
School 
Secondary/ 
High School 
Undergrad/Post 
Grad 
Missing 
Processes of Care  (n= 1,391)  (n= 1,545)  (n= 965)  (n= 1,837)  (n= 3,184)  (n= 2,311)  (n= 437)  (n= 2,185) 
1. Number of visits 
with family doctor in 
2009 (mean) 
9.55  9.79  9.52  6.6  10.04  10.07  9.64  7.34 
   [9.32;9.79]  [9.52;10.06]  [9.23;9.80]  [6.37;6.82] 
[9.91;10.18
] 
[9.89;10.26]  [9.26;10.02] 
[7.15;7.53
] 
2. Comprehensive foot 
exam  
0.61  0.56  0.52  0.01  0.59  0.54  0.53  0.01 
   [0.58;0.63]  [0.53;0.58]  [0.49;0.55]  [0.00;0.01]  [0.57;0.61]  [0.52;0.56]  [0.48;0.58] 
[0.01;0.02
] 
3. Referral to 
ophthalmologist  
0.21  0.2  0.19  0.12  0.23  0.21  0.17  0.13 
   [0.19;0.23]  [0.18;0.22]  [0.16;0.21]  [0.10;0.13]  [0.21;0.24]  [0.19;0.22]  [0.13;0.20] 
[0.12;0.15
] 
4. Glucose test ordered  0.76  0.75  0.68  0.61  0.79  0.74  0.68  0.63 
   [0.74;0.78]  [0.73;0.77]  [0.65;0.71]  [0.58;0.63]  [0.77;0.80]  [0.72;0.76]  [0.64;0.73]  [0.60;0.65
95
 
 96 
 
  Male  Female 
] 
5. At least 3 glucose 
measurements 
0.47  0.41  0.36  0.22  0.52  0.42  0.39  0.26 
   [0.44;0.49]  [0.38;0.43]  [0.33;0.39]  [0.20;0.24]  [0.50;0.53]  [0.40;0.44]  [0.34;0.43] 
[0.24;0.28
] 
6. At least 3 blood 
pressure measurements 
0.93  0.92  0.91  0.68  0.94  0.94  0.92  0.76 
   [0.92;0.94]  [0.91;0.93]  [0.89;0.93]  [0.66;0.70]  [0.93;0.95]  [0.93;0.95]  [0.89;0.95] 
[0.75;0.78
] 
7. Cholesterol 
measurement among 
patients‘ with  
dyslipidemia  
0.64  0.66  0.61  0.46  0.7  0.64  0.64  0.51 
   [0.61;0.68]  [0.62;0.69]  [0.57;0.66]  [0.43;0.49]  [0.67;0.72]  [0.61;0.67]  [0.57;0.71] 
[0.48;0.54
] 
8.Metformin 
prescribed among 
overweight patients 
without 
contraindications 
0.55  0.59  0.63  0.54  0.6  0.67  0.68  0.57 
   [0.52;0.58]  [0.56;0.62]  [0.59;0.66]  [0.51;0.57]  [0.58;0.62]  [0.65;0.69]  [0.63;0.73] 
[0.54;0.59
] 
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  Male  Female 
9. ACEI prescribed 
among patients with 
hypertension without 
contraindications 
0.63  0.58  0.57  0.61  0.52  0.52  0.47  0.52 
   [0.60;0.66]  [0.55;0.62]  [0.53;0.60]  [0.58;0.64]  [0.50;0.54]  [0.49;0.54]  [0.41;0.52] 
[0.49;0.55
] 
10. Aspirin prescribed 
among patients over 
40 years with risk 
factors and without 
contraindications 
0.45  0.4  0.43  0.39  0.41  0.36  0.34  0.33 
   [0.43;0.48]  [0.37;0.43]  [0.39;0.46]  [0.36;0.42]  [0.39;0.43]  [0.34;0.38]  [0.29;0.39] 
[0.31;0.36
] 
11. Statins prescribed 
among patients with 
total cholesterol > 
200mg/dl  and without 
contraindications 
0.49  0.53  0.53  0.54  0.5  0.5  0.54  0.45 
  [0.44;0.54]  [0.49;0.58]  [0.47;0.59]  [0.49;0.58]  [0.48;0.53]  [0.47;0.54]  [0.46;0.62] 
[0.42;0.49
] 
 Clinical Outcomes                         
12. Glucose < 
130mg/dl in each of 
last three 
0.19  0.23  0.25  0.2  0.19  0.2  0.25 
0.23 
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  Male  Female 
measurements 
   [0.16;0.22]  [0.20;0.26]  [0.21;0.30]  [0.17;0.24]  [0.17;0.21]  [0.17;0.22]  [0.19;0.32] 
[0.20;0.27
] 
13. Total cholesterol < 
200mg/dl 
0.64  0.57  0.58  0.59  0.47  0.48  0.51  0.47 
   [0.61;0.67]  [0.54;0.59]  [0.54;0.62]  [0.56;0.62]  [0.45;0.49]  [0.45;0.50]  [0.46;0.57] 
[0.44;0.49
] 
14. Systolic pressure < 
130mmHg  in each of 
last three 
measurements 
0.38  0.43  0.38  0.47  0.37  0.42  0.44  0.49 
   [0.36;0.41]  [0.41;0.46]  [0.35;0.41]  [0.44;0.49]  [0.36;0.39]  [0.40;0.44]  [0.39;0.49] 
[0.46;0.51
] 
15. Diastolic pressure 
less than 80mmHg in 
each of last three 
measurements 
0.12  0.12  0.13  0.14  0.14  0.13  0.1  0.13 
   [0.10;0.14]  [0.10;0.14]  [0.11;0.16]  [0.12;0.15]  [0.13;0.16]  [0.12;0.15]  [0.07;0.13] 
[0.11;0.14
] 
16. No diabetic 
complications± 
0.38  0.35  0.31  0.26  0.34  0.26  0.2 
0.23 
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  Male  Female 
   [0.36;0.41]  [0.33;0.38]  [0.28;0.33]  [0.24;0.28]  [0.32;0.35]  [0.25;0.28]  [0.16;0.24] 
[0.21;0.25
] 
95% Confidence intervals in parenthesis 
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